Document:

EX-10.1

 Exhibit 10.1 

SEPARATION AGREEMENT 

This Separation Agreement (this “Agreement”), entered into as of September 11, 2016, confirms the following
understandings and agreements between Weight Watchers International, Inc. (collectively with its subsidiaries, the “Company”) and James Chambers (hereinafter referred to as “you” or “your”).

 In consideration of the promises set forth herein, you and the Company agree as follows: 

 

	 	1.	Resignation from Offices; Termination of Employment. 

 (a) You hereby confirm and the
Company hereby acknowledges your resignation by mutual agreement, (i) effective as of the date hereof (the “Board Resignation Date”), from your positions as a member of the Board of Directors of the Company (the
“Board”) and as a director of any of the Company’s affiliates, and (ii) effective as of September 30, 2016 (the “CEO Resignation Date”), from your positions as Chief Executive Officer of the Company and as an
officer in any other capacity for the Company and its affiliates. Additionally, you and the Company hereby acknowledge and agree that your employment with the Company will terminate by mutual agreement effective as of the close of business on
December 31, 2016.
 (b) Subject to your execution and non-revocation of the Release of Claims attached as Exhibit A hereto as of the date
hereof, the Company hereby agrees to continue your employment during the period commencing on the Board Resignation Date and ending on December 31, 2016 (the “Transition Period”) under the terms set forth in this paragraph 1(b),
notwithstanding your resignation of positions and offices as provided in subparagraph (a) above. During the Transition Period, (i) you agree to remain employed with the Company as its Chief Executive Officer through the CEO Resignation Date
(provided that the Board may direct you to limit the scope of your activities and actions as Chief Executive Officer during such period) and to immediately thereafter remain employed as Special Advisor, performing such duties as are assigned to you
by the Office of the Chief Executive Officer (or any subsequently appointed Chief Executive Officer) and/or the Board, (ii) the Company will not terminate your employment other than for “Cause” (as defined in the Terms and Conditions for
Employee Stock Awards governing your outstanding equity awards from the Company), (iii) the Company will continue to pay you your base salary at your current annualized rate of $1,053,700 through the CEO Resignation Date and the Company will then
pay you a base salary at the rate of $10,000 per month for the period commencing on the day after the CEO Resignation Date through the end of the Transition Period, (iv) you will utilize (and not receive payment in respect of) your remaining
vacation and any other paid time off days and (v) you shall continue to be entitled to participate in all employee benefit plans to which you are currently participating (to the extent such benefits continue to be offered to similarly situated
Company employees), except that your outstanding equity awards will be treated as described in paragraph 2(b) below.
 (c) Unless
terminated earlier by the Company for Cause, your termination of employment with the Company shall be effective on the close of business on December 31, 2016 (such date, or such earlier date of termination for Cause, hereinafter referred to as the
“Separation Date”), and from and after the Separation Date you will not represent yourself as being an employee, officer, agent or representative of the Company.

	 	2.	Separation Payments. 

 (a) The Separation Date shall be the termination date of your
employment for purposes of participation in and coverage under all benefit plans and programs sponsored by or through the Company. In connection with your separation from employment with the Company, you will receive (i) any accrued but unpaid
base salary through the Separation Date, to be paid on the next regularly scheduled payroll date immediately following the Separation Date, (ii) reimbursement for any properly submitted, but unreimbursed, business expenses incurred on or prior to
the Separation Date and in accordance with the Company’s expense policy (to be eligible for such reimbursement, you must submit any such expenses within forty five (45) days of the Separation Date), and (iii) payment for any accrued but unused
vacation time in accordance with the Company’s vacation policy. In addition, you will be entitled to receive vested benefits provided under any employee benefit plans maintained by the Company and in which you participate (excluding any
employee benefit plan providing severance or similar benefits), in each case, in accordance with the terms of such plan and applicable law. 

(b) All of your outstanding Company equity awards, including stock options, restricted stock units and performance stock units granted to you
that are outstanding as of the date hereof (“Equity Awards”) will continue to vest in accordance with the terms of the relevant stock plans and equity award agreements until the Separation Date, at which point any of your then
outstanding unvested Equity Awards will be forfeited, and the post-termination of employment exercise period applicable to your outstanding vested stock options pursuant to the applicable award agreements will be deemed to commence as of your
Separation Date; provided, however, that your post-termination of employment “Noncompete Period” as defined under your Equity Award agreements will be deemed to commence as of the CEO Resignation Date. Except as
described in the preceding sentence, your vested Equity Awards shall continue to be governed by the terms of the applicable equity plan, including the Weight Watchers International, Inc. 2004 Stock Incentive Plan, the Weight Watchers International,
Inc. 2008 Stock Incentive Plan and the Weight Watchers International, Inc. 2014 Stock Incentive Plan (each as amended from time to time), and any other agreements executed thereunder and the Company’s corresponding Terms and Conditions for
Employee Stock Awards and the Term Sheets for the same, as applicable, including without limitation, any restrictive covenants contained therein and applicable to such Equity Awards. 

(c) Subject to (i) your employment during the Transition Period not being terminated for Cause, (ii) your continued compliance with the terms
of this Agreement, (iii) your re-execution of the Release of Claims attached hereto as Exhibit A during the 21 day period immediately following the Separation Date (such re-executed Release of Claims, the “Bring-Down Release”), and
(iv) the Bring-Down Release becoming effective in accordance with its terms on the Release Effective Date (as such term is defined in Exhibit A) applicable to such Bring-Down Release, the Company will provide you with the following payments and
benefits (collectively, the “Consideration”): 
 (i) A lump sum payment in an amount equal to $2,107,400
(representing one (1) times your current base salary plus your target annual bonus) (i.e., $1,053,700 plus $1,053,700), to be paid within 30 days following the Release Effective Date applicable to the Bring-Down Release; 

  
 2 

 (ii) Provided you make the necessary election, payment for your continued health
coverage under the Company-sponsored health plans pursuant to the Consolidated Omnibus Budget Reconciliation Act during the twelve (12) month period following the Separation Date, or such shorter period of time if you obtain alternative health
coverage from another employer; you agree to notify the Company of any such alternative health coverage promptly upon the commencement of such coverage; and 

(iii) Reimbursement of your reasonable legal fees and expenses incurred in connection with your negotiation of this Agreement
up to an amount equal to $15,000. Such reimbursement shall be made within thirty (30) days following the Release Effective Date applicable to the Bring-Down Release. 

(d) You acknowledge and agree that the payment(s) and other benefits provided pursuant to this paragraph 2 are being made in full
discharge of any and all liabilities and obligations of the Company to you, monetarily or with respect to employee benefits or otherwise, including but not limited to any and all obligations arising under your letter agreements with the Company
dated December 6, 2012, May 8, 2013 and July 30, 2013, and any other alleged written or oral employment agreement, policy, plan or procedure of the Company and/or any alleged understanding or arrangement between you and the Company (other than
claims for accrued and vested Equity Awards and benefits under an employee benefit, insurance, or pension plan of the Company (excluding any employee benefit plan providing severance or similar benefits), subject to the terms and conditions of such
plan(s)). 
 (e) You acknowledge that the Company may withhold from any payments made under this Agreement all applicable taxes,
including but not limited to income, employment, and social insurance taxes, as may be required by law. 
 3. Release and Waiver of
Claims. In consideration of your rights and the Company’s commitments under paragraph 1(b), you hereby agree to execute the Release of Claims attached hereto as Exhibit A simultaneously with your execution of this
Agreement. Additionally, as a condition of your right to receive the Consideration, you hereby agree to re-execute the Release of Claims attached hereto as Exhibit A as a Bring-Down Release (as described above) within 21 days following the
Separation Date. In the event of your revocation of the Release of Claims executed on the date hereof or your failure to execute or your revocation of the Bring-Down Release, you will forfeit your rights to the payments and benefits described
under paragraph 1(b) and to the Consideration, as applicable. 
 4. No Suit. You represent and warrant that you have not
previously filed, and to the maximum extent permitted by law agree that you will not file, a complaint, charge or lawsuit regarding any of the claims released herein against any of the Company. If, notwithstanding this representation and
warranty, you have filed or file such a complaint, charge or lawsuit, you agree that you shall cause such complaint, charge or lawsuit to be dismissed with 

  
 3 

 
prejudice and shall pay any and all costs required in obtaining dismissal of such complaint, charge or lawsuit, including without limitation the attorneys’ fees of any of the Company Parties
(as defined in Exhibit A) against whom you have filed such a complaint, charge, or lawsuit.
 5. Affirmative Covenants. 

(a) The parties agree that the Covenant Not to Compete, Confidentiality Information, No Raid, and Specific Performance provisions (regardless
of how such clauses may be entitled) contained in the various Terms and Conditions for Employee Stock Awards applicable to any Equity Awards are incorporated as if fully set out herein. 

(b) You shall refrain at all times after the Board Resignation Date from making any oral or written statements to third parties about the
Company or any of its affiliates, or any of such entities’ officers, employees, agents, or representatives that are disparaging, slanderous, libelous, or defamatory. The Company shall direct its officers and directors to refrain at all
times after the Board Resignation Date from making any oral or written statements to third parties about you that are disparaging, slanderous, libelous, or defamatory. The obligations under this paragraph 5(b) shall not apply to
disclosures required by applicable law, regulation or order of a court or governmental agency. 
 (c) Nothing in this Agreement or in the
Release of Claims attached hereto shall prohibit or impede you from communicating, cooperating or filing a complaint with any U.S. federal, state or local governmental or law enforcement branch, agency or entity (collectively, a
“Governmental Entity”) with respect to possible violations of any U.S. federal, state or local law or regulation, or otherwise making disclosures to any Governmental Entity, in each case, that are protected under the whistleblower
provisions of any such law or regulation, provided that in each case such communications and disclosures are consistent with applicable law. You do not need the prior authorization of (or to give notice to) the Company regarding any such
communication or disclosure. You hereby confirm that you understand and acknowledge that an individual shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made
(i) in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or (ii) in a complaint or other document filed in a lawsuit or other proceeding,
if such filing is made under seal. You understand and acknowledge further that an individual who files a lawsuit for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the attorney of the
individual and use the trade secret information in the court proceeding, if the individual files any document containing the trade secret under seal; and does not disclose the trade secret, except pursuant to court order. Notwithstanding the
foregoing, under no circumstance will you be authorized to disclose any information covered by attorney-client privilege or attorney work product of the Company without prior written consent of the Company’s General Counsel or other officer
designated by the Company. 
 (d) Without limiting any other remedy available to the Company, in the event you breach any of the provisions
of this paragraph 5, the Company’s obligations to provide you the Consideration shall cease. 

  
 4 

 6. Cooperation. 

(a) You agree that you will provide reasonable cooperation to the Company and its counsel in connection with any investigation,
administrative proceeding or litigation relating to any matter that occurred during your employment in which you were involved or of which you have knowledge. In consideration for your compliance with this paragraph, the Company agrees to
reimburse you for reasonable out-of-pocket expenses incurred at the request of the Company (including, if reasonably necessary in connection with your participation in a legal proceeding, reimbursement for counsel fees provided that such counsel is
approved by the Company or otherwise provided by the Company). The Company agrees that any requests for cooperation shall take into account and accommodate your employment obligations following the Separation Date. 

(b) You agree that, in the event you are subpoenaed by any person or entity (including, but not limited to, any government agency) to give
testimony or provide documents (in a deposition, court proceeding or otherwise) which in any way relates to your employment by the Company, you will give prompt notice of such request to the Company’s General Counsel and will make no disclosure
until the Company has had a reasonable opportunity to contest the right of the requesting person or entity to such disclosure. 
 7.
Return of Property. You agree that you will promptly return to the Company all property belonging to the Company, including but not limited to all proprietary and/or confidential information and documents (including any copies thereof)
in any form belonging to the Company, and any beeper, keys, card access to the building and office floors, Employee Handbook, phone card, computer user name and password, disks and/or voicemail code; provided, however, that you will be
permitted to keep your Company issued cell phone, iPad and laptop computer after the Company has removed all confidential information from such devices. 

8. Successors and Assigns. The provisions hereof shall inure to the benefit of your heirs, executors, administrators, legal
personal representatives and assigns and shall be binding upon your heirs, executors, administrators, legal personal representatives and assigns. 

9. Severability. If any provision of this Agreement shall be held by any court of competent jurisdiction to be illegal, void or
unenforceable, such provision shall be of no force and effect. The illegality or unenforceability of such provision, however, shall have no effect upon and shall not impair the enforceability of any other provision of this Agreement. 

10. Non-Admission. Nothing contained in this Agreement will be deemed or construed as an admission of wrongdoing or liability on
the part of you or the Company. 
 11. Entire Agreement. This Agreement and the Release of Claims attached hereto constitutes
the entire understanding and agreement of the parties hereto regarding the termination of your employment. This Agreement supersedes all prior negotiations, discussions, correspondence, communications, understandings and agreements between the
parties relating to the subject matter of this Agreement. 

  
 5 

 12. 409A. This Agreement is intended to comply with Section 409A of the Internal
Revenue Code of 1986, as amended (the “Code”) and will be interpreted in a manner intended to comply with Section 409A of the Code (and any related regulations or other pronouncements). Amounts payable under this Agreement shall be
deemed not to be a “deferral of compensation” subject to Section 409A of the Code to the extent provided in the exceptions set forth in Treas. Reg. Section 1.409A-1(b)(4) (“short-term deferrals”) and Treas. Reg. Section
1.409A-1(b)(9) (“separation pay plans”) and other applicable provisions of Treas. Reg. Section 1.409A-1 through A-6. References under this Agreement to a termination of your employment shall be deemed to refer to the date upon which you
have experienced a “separation from service” within the meaning of Section 409A of the Code. Each payment made under this Agreement shall be designated as a “separate payment” within the meaning of Section 409A of the Code. For
the avoidance of doubt, any continued health benefit plan coverage that you are entitled to receive following your termination of employment is expected to be exempt from Section 409A of the Code and, as such, shall not be subject to delay pursuant
to this paragraph. To the extent that any reimbursement, fringe benefit, or other similar arrangement provided herein provides for a “deferral of compensation” within the meaning of Section 409A of the Code, (i) the right to reimbursement
or in-kind benefits shall not be subject to liquidation or exchange for another benefit; (ii) the amount eligible for reimbursement or payment in one calendar year may not affect the amount eligible for reimbursement or payment in any other calendar
year (except that a plan providing medical or health benefits may impose a generally applicable limit on the amount that may be reimbursed or paid); (iii) subject to any shorter time periods provided in any expense reimbursement policy of the
Company, any reimbursement or payment of an expense under such plan or arrangement must be made on or before the last day of the calendar year following the calendar year in which the expense was incurred; and (iv) the reimbursements shall be made
pursuant to objectively determinable and nondiscretionary Company policies and procedures regarding such reimbursement of expenses. While the payments and benefits provided hereunder are intended to be structured in a manner to avoid the implication
of any penalty taxes under Section 409A of the Code, in no event whatsoever shall the Company or any of its affiliates be liable for any additional tax, interest or penalties that may be imposed on you as a result of Section 409A of the Code or any
damages for failing to comply with Section 409A of the Code (other than for withholding obligations or other obligations applicable to employers, if any, under Section 409A of the Code). 

  
 6 

 13. Governing Law; Jurisdiction. THIS AGREEMENT SHALL BE GOVERNED AND CONFORMED IN
ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. IN THE EVENT THAT YOU OR THE COMPANY BREACHES ANY PROVISION OF THIS AGREEMENT, YOU AND THE COMPANY AFFIRM THAT EITHER MAY INSTITUTE AN ACTION TO SPECIFICALLY ENFORCE ANY TERM OF THIS
AGREEMENT. EACH PARTY HERETO HEREBY CONSENTS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS LOCATED IN THE STATE OF NEW YORK, IN AND FOR THE COUNTY OF NEW YORK, OR THE UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW
YORK, FOR THE RESOLUTION OF ANY DISPUTE REGARDING OR ARISING OUT OF THIS AGREEMENT. ANY CLAIM SHALL BE HEARD BY A JUDGE OF THAT COURT, WITHOUT A JURY. IF ANY PROVISION OF THIS AGREEMENT IS DECLARED ILLEGAL OR UNENFORCEABLE BY ANY COURT OF
COMPETENT JURISDICTION, THE PARTIES AGREE THE COURT SHALL HAVE THE AUTHORITY TO MODIFY, ALTER OR CHANGE THE PROVISION(S) IN QUESTION TO MAKE THE AGREEMENT LEGAL AND ENFORCEABLE. IF THIS AGREEMENT CANNOT BE MODIFIED TO BE ENFORCEABLE, SUCH
PROVISION SHALL IMMEDIATELY BECOME NULL AND VOID, LEAVING THE REMAINDER OF THIS AGREEMENT IN FULL FORCE AND EFFECT.  

*    *    * 

  
 7 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date set forth
below. 
  

			
	WEIGHT WATCHERS INTERNATIONAL, INC.
		
	By:	 	 /s/ Raymond Debbane

	Name:	 	Raymond Debbane
	Title:	 	Chairman
	
	 /s/ James Chambers

	James Chambers

  
 8 

 EXHIBIT A 

to 
 Separation Agreement

 RELEASE OF CLAIMS 

As used in this Release of Claims (this “Release”), the term “claims” will include all claims, covenants,
warranties, promises, undertakings, actions, suits, causes of action, obligations, debts, accounts, attorneys’ fees, judgments, losses and liabilities, of whatsoever kind or nature, in law, equity or otherwise. Capitalized terms not
otherwise defined herein shall have the meaning set forth in my Separation Agreement, dated September 11, 2016, and to which this Release is attached as an Exhibit (the “Separation Agreement”). 

I intend the release contained herein to be a general release of any and all claims to the fullest extent permissible by law.

For and in consideration of the foregoing, the payments and benefits described in the Separation Agreement, and other good and valuable
consideration, I, for and on behalf of myself and my heirs, administrators, executors and assigns, effective the date hereof, do fully and forever release, remise and discharge the Company and its affiliates, together with their respective current
and former officers, directors, partners, members, shareholders, fiduciaries, counsel, employees and agents (collectively, and with the Company, the “Company Parties”) from any and all claims whatsoever up to the date hereof
which I had, may have had, or now have against the Company Parties, for or by reason of any matter, cause or thing whatsoever, including any claim arising out of or attributable to my employment or the termination of my employment with the Company
or otherwise, whether for (by way of example only) tort, breach of express or implied employment contract, intentional infliction of emotional distress, wrongful termination, unjust dismissal, defamation, libel or slander, or under any federal,
state or local law, rule or regulation, or the common law, dealing with employment, including, but not limited to, discrimination in employment based on age, race, sex, national origin, handicap, religion, disability or sexual orientation. This
release of claims includes, but is not limited to, all claims arising under the Age Discrimination in Employment Act (“ADEA”), Title VII of the Civil Rights Act, the Americans with Disabilities Act, the Civil Rights Act of 1991, the
Family Medical Leave Act, and the Equal Pay Act, each as may be amended from time to time, and all other federal, state and local laws, the common law and any other purported restriction on an employer’s right to terminate the employment of
employees. 
 I acknowledge and agree that as of the date of the execution of this Release, I have no knowledge of any facts or
circumstances that give rise or could give rise to any claims, including any claims under any of the laws listed in the preceding paragraph. 

By executing this Release, I specifically release all claims relating to my employment and its termination under ADEA, a United States
federal statute that, among other things, prohibits discrimination on the basis of age in employment and employee benefit plans. 

Notwithstanding the foregoing, nothing in this Release shall be a waiver of: (i) any claim by me to enforce the terms of this Release or the
Separation Agreement, including any rights with respect to payment of amounts and provision of benefits under the Separation Agreement, (ii) any claims that cannot be waived by law including, without limitation any claims

 
filed with the Equal Employment Opportunity Commission, the U.S. Department of Labor, or claims under the ADEA that arise after the date of this Agreement, or (iii) my right of indemnification
and D&O coverage by virtue of my service as an officer, whether by agreement, common law, statute or pursuant to the Company’s Certificate of Incorporation, as amended to date. 

I acknowledge and agree that by virtue of the foregoing, I have waived any relief available (including without limitation, monetary damages,
equitable relief and reinstatement) under any of the claims and/or causes of action waived in this Release. Therefore I agree not to accept any award or settlement from any source or proceeding (including but not limited to any proceeding
brought by any other person or by any government agency) with respect to any claim or right waived in this Release. 
 I represent and
warrant that I have not previously filed any complaint, charge or lawsuit regarding any of the claims released herein against any of the Company Parties. 

I expressly acknowledge and agree that I: 
  

	 	•	 	Am able to read the language, and understand the meaning and effect, of this Release; 

  

	 	•	 	Have no physical or mental impairment of any kind that has interfered with my ability to read and understand the meaning of this Release or its terms, and that I am not acting under the influence of any medication, drug
or chemical of any type in entering into this Release; 

  

	 	•	 	Am specifically agreeing to the terms of the release contained in this Release because the Company has agreed to pay me the payments and benefits described in the Separation Agreement, which the Company has agreed to
provide because of my agreement to accept it in full settlement of all possible claims I might have or ever had, and because of my execution of this Release; 

  

	 	•	 	Acknowledge that but for my execution of this Release, I would not be entitled to the payments and benefits described in the Separation Agreement; 

 

	 	•	 	Understand that, by entering into this Release, I do not waive rights or claims under ADEA that may arise after the date I execute this Release; 

 

	 	•	 	Had or could have until twenty one days following my receipt of this Release (the “Review Period”) in which to review and consider this Release, and that if I execute this Release prior to the
expiration of the Review Period, I have voluntarily and knowingly waived the remainder of the Review Period; 

  

	 	•	 	Was advised to consult with my attorney regarding the terms and effect of this Release; and 

  

	 	•	 	Have signed this Release knowingly and voluntarily. 

  
 10 

 Notwithstanding anything contained herein to the contrary, this Release will not become effective
or enforceable prior to the expiration of the period of seven (7) calendar days following the date of its execution by me (the “Revocation Period”), during which time I may revoke my acceptance of this Release by notifying the
Company, in writing, delivered to the Company at its principal executive office, marked for the attention of its General Counsel. To be effective, such revocation must be received by the Company on or prior to the seventh (7th) calendar day following the execution of this Release. Provided that the Release of Claims is executed and I do not revoke it during the Revocation Period, the eighth (8th) day following the date on which this Release is executed shall be its effective date (the “Release Effective Date”). I acknowledge and agree that if I revoke
this Release during the Revocation Period, this Release will be null and void and of no effect, and the Company will be released of any obligations under the Separation Agreement. 

The provisions of this Release shall be binding upon my heirs, executors, administrators, legal personal representatives, assigns and
successors. If any provision of this Release shall be held by any court of competent jurisdiction to be illegal, void, or unenforceable, such provision shall be of no force or effect. The illegality or unenforceability of such provision,
however, shall have no effect upon and shall not impair the enforceability of any other provision of this Release. 
 THIS RELEASE SHALL BE
GOVERNED AND CONFORMED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK. I HEREBY CONSENT TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS LOCATED IN THE STATE OF NEW YORK, IN AND FOR THE COUNTY OF NEW YORK, OR THE UNITED
STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK, FOR THE RESOLUTION OF ANY DISPUTE REGARDING OR ARISING OUT OF THIS RELEASE. ANY CLAIM SHALL BE HEARD BY A JUDGE OF THAT COURT, WITHOUT A JURY. IF THIS RELEASE IS DECLARED ILLEGAL
OR UNENFORCEABLE BY ANY COURT OF COMPETENT JURISDICTION, I AGREE TO EXECUTE A BINDING REPLACEMENT RELEASE OR, IF REQUESTED BY THE COMPANY, TO RETURN THE MONIES PAID PURSUANT TO THE SEPARATION AGREEMENT OR TO APPLY THE AMOUNTS RECEIVED UNDER THE
SEPARATION AGREEMENT AS A SET-OFF TO ANY CLAIM OR RELIEF. 
  

	
	  

	James Chambers
	Dated:

  
 11EX-10.3

 Exhibit 10.3 

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

 RESEARCH COLLABORATION AND LICENSE AGREEMENT 

This Research Collaboration and License Agreement (“Agreement”) is made and entered into as of the 15th day of June 2012 (the
“Effective Date”) by and between AC Immune SA Corporation, a Swiss corporation with a principal place of business at Parc scientifique EPFL, PSE-B, CH-1015 Lausanne, Switzerland (“ACI”) and Genentech, Inc., a
Delaware corporation, with offices located at 1 DNA Way, South San Francisco, CA 94080 (“GNE”) and F. Hoffmann-La Roche Ltd, a Swiss corporation with its principal place of business at Grenzacherstrasse 124, CH 4070 Basel,
Switzerland (“Roche”) (GNE and Roche, collectively, “Genentech”). ACI and Genentech are each referred to herein individually as a “Party” and collectively as the “Parties.” 

RECITALS 
 WHEREAS ACI possesses
certain expertise and proprietary technologies related to antibody products that interact with tau protein and its derivatives. 
 WHEREAS
ACI and Genentech wish to collaborate in further research related to antibody materials that interact with tau protein and its derivatives for the diagnosis, prevention and treatment of diseases; 

WHEREAS Genentech is a health care company with expertise and capability in researching, developing, manufacturing and marketing human
therapeutics and diagnostics; 
 WHEREAS, ACI and Genentech wish to enter into an exclusive licensing arrangement whereby Genentech will
have exclusive rights to research, develop and commercialize antibody products that interact with tau protein derivatives for the selection and evaluation of patients and the treatment of Alzheimer’s disease and other indications in exchange
for upfront, milestone and royalty payments. 
 NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other
good and valuable consideration, the amount and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: 

ARTICLE 1: DEFINITIONS 

1.1 “ACI Antibodies” means all Tau-Active Antibodies that are owned or Controlled by ACI as of the Effective Date, or during
the Term of this Agreement, or provided by, or on behalf of, ACI to the Research Program; but [*****]. 
 1.2 “ACI Confidential
Information” means Confidential Information disclosed or provided by, or on behalf of, ACI to Genentech or its designees, other than [*****]. 

1.3 “ACI IP Rights” means (i) all Patents which claim Tau-Active Antibodies (including assays, and methods of
immunization to generate, methods of making or methods of using any of the foregoing) or methods of screening or detecting Tau interaction, binding or modulation activity, which Patents include but are not limited to those set forth on Exhibit
A, and (ii) all other intellectual property rights in and to Know-How related to Licensed Products and Tau-Active Antibodies (including assays, and methods of immunization to generate, methods of making or methods of using any of the
foregoing) or methods of screening or detecting Tau interaction, binding or modulation activity; in each case (a) owned or Controlled by ACI or its Affiliates as of the Effective Date or during the Term of this 

 
  

			
	Research Collaboration and License Agreement (Tau)	  	1

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 
Agreement, which shall include (A) those antibodies that have been generated as of the Effective Date utilizing the antigens set forth on Exhibit C but have not yet been sequenced or
characterized and (B) those antibodies that will be generated by ACI through the use of the antigens listed on Exhibit C (each in clauses (A) and (B), a “Discovery Antibody” or collectively the “Discovery
Antibodies”) (b) excluding (1) any [*****], (2) any claims which are specific to [*****], but in each case except to the extent rights to and under such claims which are specific to a [*****] are necessary for Genentech to
fully exploit its rights and activities as contemplated in this Agreement, including research, development and commercialization of Licensed Products in the Genentech Field and (3) any claims specifically directed to methods for producing
antibodies other than Tau-Active Antibodies [*****] Tau. 
 1.4 “ACI Licensee” means any Third Party which enters into an
agreement with ACI or an Affiliate of ACI involving the grant to such Third Party of a right to make, use, sell, offer for sale or import a Tau-Active Antibody outside the Genentech Field. 

1.5 “ACI Program IP Rights” has the meaning set forth in Section 7.2.1. 

1.6 “Additional Indication” means any disease condition, [*****]. 

1.7 “Affiliate” means any Person that, directly or indirectly (through one or more intermediaries) controls, is controlled
by, or is under common control with a Party. For purposes of this Section 1.9, “control” means (i) the direct or indirect ownership of fifty percent (50%) or more of the voting stock or other voting interests
or interest in the profits of the Party, or (ii) the ability to otherwise control or direct the decisions of the board of directors or equivalent governing body thereof. For purposes of this Agreement, with respect to Genentech, the term
“Affiliate” shall not include [*****] and its successors, or any entity that controls, is controlled by or is under common control with [*****], in each case that is not controlled by Genentech unless and until GNE [*****] provides
written notice to ACI specifying [*****] as an Affiliate of Genentech. 
 1.8 “Applicable Laws” means all applicable
statutes, ordinances, regulations, rules, or orders of any kind whatsoever of any government or regulatory authority, or court, of competent jurisdiction. 

1.9 “BLA” means a complete biologics license application as defined in, and containing the content, and in the format,
required by 21 C.F.R. § 600 et seq filed with the FDA, or a corresponding application with a Regulatory Authority in a country other than the United States, together with all replacements, additions, deletions, and supplements thereto. 

1.10 “Blocking Third Party Intellectual Property” has the meaning set forth in Section 5.7.2. 

1.11 “Business Day(s)” means any day, other than a Saturday, Sunday or day on which commercial banks located in San Francisco
or Lausanne are authorized or required by law or regulation to close. 
 1.12 “Change in Control” has the meaning set forth
in Section 14.3. 
 1.13 “Commercially Reasonable Efforts” means the exercise of such efforts and commitment of such
resources by [*****] 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	2

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 [*****]. 

1.14 “Competitor” has the meaning set forth in Section 14.3. 

1.15 “Confidential Information” means (i) all information and materials (of whatever kind and in whatever form or
medium) disclosed by or on behalf of a Party to the other Party (or its designee) in connection with this Agreement, including any Know-How, whether prior to or during the term of this Agreement (including any such information and materials
disclosed pursuant to the Confidential Disclosure Agreement between the Parties dated March 18, 2010, as amended) and whether provided orally, electronically, visually, or in writing; (ii) all copies of the information and materials
described in (i) above; and (iii) the existence and each of the terms and conditions of this Agreement. “Confidential Information” shall not include, to the extent a Party can demonstrate, through its contemporaneous
written records, information and materials (a) known to the receiving Party, or in the public domain, at the time of its receipt by a Party, or which thereafter becomes part of the public domain other than by virtue of a breach of this
Agreement or the obligations of confidentiality under this Agreement; (b) received without an obligation of confidentiality from a Third Party having the right to disclose without restriction such information; (c) independently developed
by the receiving Party without use of or reference to Confidential Information disclosed by the other Party; and (d) released from the restrictions set forth in this Agreement by the express prior written consent of the disclosing Party. 

1.16 “Control(s)” or “Controlled” means the possession by a Party, as of the Effective Date or during the
term of this Agreement, with respect to Know How or Patent rights either (i) physical possession or the right to such physical possession of those items, with the right to provide them to Third Parties; or (ii) rights sufficient to grant
the applicable license or sublicense under this Agreement, in each case without violating the terms of any agreement with any Third Party. 

1.17 “CRO” means a Third Party contract research organization. 

1.18 “Covers” or “Covered by,” or the like, with reference to a particular Licensed Product means that the
making, using, selling, offering for sale, or importing of such Licensed Product would, but for ownership of, or a license granted under this Agreement to, the relevant Patent infringe a Valid Patent Claim of the relevant Patent in the country in
which the activity occurs. 
 1.19 “Diagnostic Field” means the detection and/or quantification of the presence or amount
of an analyte in body fluids or tissue that affects the pathogenesis of any disease or a biological marker or a set of biological markers shown to indicate a predisposition to any disease. 

1.20 “Diagnostic Net Sales” mean, with respect to sales or other dispositions of a Diagnostic Product, [*****] 

 

	 	a)	[*****] 

  

	 	b)	[*****] 

 [*****] 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	3

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 [*****] 

[*****] 
 [*****] 

[*****] 
 1.21
“Diagnostic Product” means any product, method or technologies in the form of a device, compound, kit or service that contains a Tau Active Antibody for use in the Diagnostic Field. 

1.22 “Discovery Antibody IP Rights” means a Valid Patent Claim within the ACI IP Rights that Covers a Discovery Antibody.

 1.23 “Discovery Antibody(ies)” has the meaning set forth in Section 1.3. 

1.24 “Dispute” has the meaning set forth in Section 13.1. 

1.25 “ED-Go Decision” has the meaning set forth in Section 5.2.1(a). 

1.26 “Effective Date” has the meaning set forth in the introductory paragraph of the Agreement. 

1.27 “EMA” means the European Medicines Agency, or any successor thereto. 

1.28 “FDA” means the U.S. Food and Drug Administration or corresponding governmental authority in another country, or any
successor thereto. 
 1.29 “Filing” or “Filed” means, with respect to an application for Marketing
Approval that such application has been filed with and accepted for review by the appropriate Regulatory Authority. 
 1.30 “First
Commercial Sale” means, with respect to a particular Licensed Product in a given country, the first bona fide arm’s length commercial sale of such Licensed Product following Marketing Approval in such country by or under authority of
Genentech, its Affiliates or Genentech Licensees to a Third Party. 
 1.31 “FTE” means a full-time person, or more than one
person working the equivalent of a full-time person, where “full-time” is determined by the standard practices in the biopharmaceutical industry in the geographic area in which such personnel are working. 

1.32 “Genentech Confidential Information” means Confidential Information disclosed or provided by, or on behalf of, Genentech
to ACI or its designees, other than Program Confidential 

  
  

			
	Research Collaboration and License Agreement Tau	  	4

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 
Information. 
 1.33 “Genentech Field” means the [*****]. 

1.34 “Genentech IP Rights” means (i) all Patents which claim a Tau-Active Antibody (including a method of making or
using a Tau-Active Antibody) or assays, methods of screening or detecting Tau interaction and (ii) all other intellectual property rights, or rights in confidential or proprietary information, relating to a Tau-Active Antibody; in each case
owned or Controlled by GNE as of the Effective Date or during the Term of this Agreement and all Genentech Program IP Rights and Genentech’s interest in the Joint Program IP Rights. Genentech IP Rights are exclusive of any ACI IP Rights
licensed to Genentech under this Agreement. 
 1.35 “Genentech Licensee(s)” means any Third Party which enters into an
agreement with Genentech or an Affiliate of Genentech involving the grant to such Third Party of a right to make, use, sell, offer for sale or import a Tau-Active Antibody or Licensed Product or a sublicense under any of the licenses granted to
Genentech hereunder. 
 1.36 “Genentech Program IP Rights” has the meaning set forth in Section 7.2.1. 

1.37 “ICC” has the meaning set forth in Section 13.2. 

1.38 “ICC Rules” has the meaning set forth in Section 13.2. 

1.39 “IFRS” shall mean the International Financial Reporting Standards (IFRS), consistently applied. 

1.40 “Improvements” has the meaning set forth in Section 7.2.2. 

1.41 “IND” means a complete “Investigational New Drug Application” as defined in 21 C.F.R. 312.3 and
containing the content, and in the format, required by 21 C.F.R. 312.23, or a corresponding application with a regulatory agency in a country other than the United States, together with all additions, deletions, and supplements thereto. 

1.42 “Joint Program IP Rights” has the meaning set forth in Section 7.2.1. 

1.43 “Joint Research Committee” or “JRC” has the meaning set forth in Section 2.2.1. 

1.44 “Know-How” means all compositions of matter, techniques and data and other know-how and technical information, including
inventions (whether or not patentable), improvements and developments, practices, methods, concepts, know-how, trade secrets, documents, computer data, computer code, apparatus, clinical and regulatory strategies, test data, analytical and quality
control data, formulation, manufacturing, patent data or descriptions, development information, drawings, specifications, designs, plans, proposals and technical data and manuals and all other proprietary information. 

1.45 “K.U. Leuven Agreement” has the meaning set forth in Section 4.3.3. 

1.46 “Licensed Product(s)” means (i) any product containing a Tau-Active Antibody for use in the Therapeutics Field or
(ii) a Diagnostic Product. [*****]. 
 1.47 “Major European Country” means Germany, France, the United Kingdom, Spain
or Italy. 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	5

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 1.48 “Marketing Approval” means all approvals, licenses, registrations or
authorizations of any federal, state or local regulatory agency, department, bureau or other governmental entity, necessary for the manufacturing, use, storage, import, transport, marketing and sale of Licensed Products in a country or regulatory
jurisdiction. For countries where governmental approval is required for pricing or reimbursement for the Licensed Product, “Marketing Approval” shall not be deemed to occur until such pricing or reimbursement approval is obtained.

 1.49 “Milestone” has the meaning set forth in Section 5.2.1. 

1.50 “Net Sales” of a Licensed Product in a particular period means [*****] 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	6

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 [*****] 

1.51 “Outside Patent Counsel” has the meaning set forth in Section 7.4.3. 

1.52 “Patent(s)” means a patent or a patent application, including any additions, divisions, continuations,
continuations-in-part, pipeline protection, invention certificates, substitutions, reissues, reexaminations, extensions, registrations, patent term extensions, supplementary protection certificates and renewals of any of the above. 

1.53 “Patent Infringement Dispute” has the meaning set forth in Section 13.3. 

1.54 “Person” means any person or entity, including any individual, trustee, corporation, partnership, trust, unincorporated
organization, limited liability company, business association, firm, joint venture or governmental agency or authority. 
 1.55
“Phase I Clinical Trial” means, as to a specific Therapeutic Product, a controlled and lawful study in humans designed with the principal purpose of preliminarily determining the safety of a pharmaceutical product in healthy
individuals or patients, and for which there are no primary endpoints related to efficacy, as further defined in 21 C.F.R. § 312.21(a); or similar clinical study in a country other than the United States. 

1.56 “Phase II Clinical Trial” means, as to a specific Therapeutic Product, a controlled and lawful study in humans designed
with the principal purpose of determining initial efficacy and dosing of such Licensed Product in patients for the indication(s) being studied, as further defined in 21 C.F.R. § 312.21(b); or similar clinical study in a country other than the
United States. 
 1.57 “Phase III Clinical Trial” means, as to a specific Therapeutic Product, a controlled and lawful
study in humans of the efficacy and safety of such Licensed Product, which is prospectively designed to demonstrate statistically whether such Licensed Product is effective and safe for use in a particular indication in a manner sufficient to file
an application to obtain Marketing Approval to market and sell that Licensed Product in the United States or another country for the indication being investigated by the study, as further defined in 21 C.F.R. § 312.21; or similar clinical study
in a country other than the United States. 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	7

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 1.58 “Product Reversion Package” means, [*****]. 

1.59 “Program Antibody” means any Tau-Active Antibody created, discovered, conceived or reduced to practice by the Parties
jointly or solely by either Party during the conduct of activities under the Research Program or Research Plan during the Research Term. 

1.60 “Program IP Rights” means (i) all Patents which claim a (including a method of making or using) Know How conceived,
reduced to practice or otherwise created during the conduct of and in connection with activities under the Research Program or Research Plan (whether solely by one Party and/or its respective employees, contractors or consultants or jointly by the
Parties and/or their employees, contractors or consultants), and (ii) all other intellectual property rights, or rights in confidential or proprietary information, in and to Know-How conceived, reduced to practice or otherwise created during
the conduct of and in connection with activities under the Research Program or Research Plan (whether solely by one Party and/or its respective employees, contractors or consultants or jointly by the Parties and/or their employees, contractors or
consultants). [*****]. 
 1.61 “Program Confidential Information” means (i) all information and materials (of whatever
kind and in whatever form or medium), including any Know-How, created by, or on behalf of, either Party, or created jointly by the Parties during the course of performing the activities contemplated by the Research Plan and (ii) all copies of
the information and materials described in (i) above. “Program Confidential Information” shall not include, to the extent a Party can demonstrate, through its contemporaneous written records, information and materials
(a) known to either Party, or in the public domain, prior to its creation hereunder, or which thereafter becomes part of the public domain other than by virtue of a breach of this Agreement or the obligations of confidentiality under the
Agreement; (b) received without an obligation of confidentiality from a Third Party having the right to disclose without restrictions such information; and (c) released from the restrictions set forth in this Agreement by the express prior
written consent of the other Party. 
 1.62 “Prosecution and Maintenance” or “Prosecute and Maintain,” has the
meaning set forth in Section 7.4.1. 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	8

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 1.63 “Regulatory Authority” means any national (e.g., the FDA),
supra-national (e.g., the EMA), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, in any jurisdiction of the world, involved in the granting of Marketing Approval. 

1.64 “Research Plan” means the written research plan for the Research Program to be prepared by the Parties in accordance
with Section 2.1. The initial draft Research Plan is set forth on Exhibit B. The Research Plan may be amended or modified from time to time by the Joint Research Committee by written agreement or as evidenced in the approved
minutes of the JRC meetings. 
 1.65 “Research Program” means the program of research and preclinical development the
Parties engage in under this Agreement, which program is set forth on the Research Plan. 
 1.66 “Research Term” means the
period of time during which each Party will undertake activities in the Research Program or on the Research Plan, as such period of time is identified in Section 2.6. 

1.67 “ROFN Period” has the meaning set forth in Section 4.5. 

1.68 “Tau” means the microtubule-associated protein known as tau and all isoforms thereof. 

1.69 “Tau-Active Antibody” means any antibody protein, including variants, modifications, fragments or derivatives thereof,
that binds to and interacts with or modulates Tau or variants, modifications, derivatives or fragments of Tau. 
 1.70
“Term” has the meaning set forth in Section 9.1. 
 1.71 “Termination Product” means a
Therapeutic Product that (a) exists as of the date of termination (but not expiration) of this Agreement and (b) contains [*****] as an active ingredient. 

1.72 “Territory” means the entire world. 

1.73 “Therapeutic Field” means the prevention, cure, amelioration or treatment of any disease or condition, in each case
other than by means of [*****]. 
 1.74 “Therapeutic Product” means any Licensed Product developed and/or marketed for use
in the Therapeutic Field, but expressly excluding [*****]. 
 1.75 “Third Party” means a Person that is not a Party to this
Agreement or an Affiliate of a Party to this Agreement. 
 1.76 “United States” means the United States of America, its
territories and possessions as of the Effective Date, including the Commonwealth of Puerto Rico. 
 1.77 “Valid Patent
Claim” means a claim of an issued and unexpired Patent which has not been disclaimed, revoked, held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within
the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise. 

1.78 “Vaccine Product” means an active vaccination product that incorporates Tau or any variant, derivative, modification, or
fragment of Tau for use as a vaccine. 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	9

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 1.79 “Vaccine Product Rights” mean (i) all Patents which claim Know-How
related to Vaccine Products (including methods of making or using Vaccine Products), and (ii) all other intellectual property rights, or rights in confidential or proprietary information, in and to Know-How specific to a Vaccine Product; in
each case owned or Controlled by ACI as of the Effective Date or during the Term of this Agreement 
 ARTICLE 2: RESEARCH PROGRAM 

2.1 Research Program Overview and Responsibilities. Under this Agreement, the Parties are establishing a Research Program directed to
the advancement and research of existing ACI Antibodies and the development of new antibodies. The Research Program will be coordinated by the Joint Research Committee. The Research Program will be described, and the Parties’ responsibilities
with respect to the Research Program will be set forth, in the Research Plan. Each Party shall use diligent efforts to perform its respective responsibilities under the Research Plan and for the Research Program, and shall cooperate with and provide
reasonable support to the other Party in such other Party’s performance of its responsibilities thereunder. 
 2.2 Joint Research
Committee. 
 2.2.1 The JRC. Within [*****] days after the Effective Date, the Parties shall establish a committee to oversee the
Research Program, and to plan and coordinate the activities under the Research Plan (“Joint Research Committee” or “JRC”). The JRC will be composed of three (3) representatives designated by each Party (or such
other number as the Parties may agree, provided that each of the Parties shall have the same number of JRC members). Representatives must be appropriate for the tasks then being undertaken and the stage of research or pre-clinical development, in
terms of their seniority, availability, function in their respective organizations, training and experience. Each Party shall designate one of its representatives as its primary JRC contact. Either Party may replace any or all of its representatives
to the JRC at any time upon prior written notice to the other Party. If a Party’s representative is unable to attend a meeting, that Party may designate an alternate representative. 

2.2.2 Meetings. The JRC shall meet at such times as are unanimously agreed to by the JRC members, but no less than once each calendar
quarter. Such meetings may be in-person, via videoconference, or via teleconference, provided that at least one meeting per calendar year shall be held in person. JRC meetings must be attended by at least one representative from each Party.
The location of in-person JRC meetings will alternate between South San Francisco, California and Lausanne, Switzerland, unless otherwise agreed to by the Parties. Each Party will bear the expense of its respective Committee members’
participation in JRC meetings. he JRC shall record all decisions made, and otherwise take minutes as appropriate. Genentech shall have the responsibility for keeping minutes. JRC meeting minutes will be sent to each member of the JRC for review as
soon as practicable after a meeting. A Party may, with the prior written consent of the other Party, invite a reasonable number of non-voting employees, consultants or scientific advisors to attend a meeting of the JRC. Those invitees must be bound
by appropriate confidentiality obligations. 
 2.2.3 Responsibilities of the JRC. Subject to Section 2.2.4, the Joint
Research Committee shall perform the following functions: 
 (i) review and amend the Research Plan, as needed; 

(ii) review the allocation of resources and efforts for the Research Program; 

(iii) monitor the progress of the Research Program; 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	10

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 (iv) subject to Section 2.3, coordinate, and be the primary
conduit for, the transfer of ACI Antibodies, Program Antibodies and related research materials, Know-How, and Confidential Information between the Parties; and 

(v) Perform such other functions referred to in the Research Plan, as appropriate to further the purposes of the Research
Program, or as otherwise specified in this Agreement or agreed to by the Parties. 
 2.2.4 Decision-Making Authority. The Joint
Research Committee will attempt to make decisions by consensus. If the JRC cannot reach consensus, then Genentech shall have final decision making authority; except for the following, which require agreement of the Parties: [*****]. 

2.3 Transfer of Know-How During Research Term. 

2.3.1 JRC Meetings and Communication. In addition to JRC meetings, project team scientists working on the Research Plan shall have
periodic meetings or teleconference or videoconference discussions. 
 2.3.2 Ongoing Transfer of ACI Antibodies and related Know-How.
Within [*****] days of the Effective Date, ACI shall deliver to Genentech: (a) a reasonable amount of research materials [*****] and (b) other Know-How related to the rights granted to Genentech by this Agreement in ACI’s control as
of the Effective Date. On an ongoing basis during the Term, ACI shall, as determined by the JRC, deliver to Genentech: (i) a reasonable amount of research materials [*****] and (ii) other Know-How created under the Research Plan or
otherwise obtained by ACI and not already in Genentech’s possession. 
 2.3.3 Written Reports. At least once every calendar
quarter during the Research Term and within [*****] following the end of the Research Term, ACI shall provide to Genentech, through the JRC, the following written communications regarding work undertaken or assigned as part of the Research Program:
(a) a written description of significant discoveries or advances, promptly after such results are obtained or their significance is appreciated; (b) a written summary of research conducted and the results thereof, including any antibodies
made or discovered, the results of in vitro and in vivo studies, any inventions conceived or reduced to practice, on at least a calendar quarter basis; (c) raw data for research undertaken under the Research Program, upon request of Genentech;
and (d) a list of the CROs performing activities during that calendar quarter and a brief summary of the work performed by each CRO. The foregoing reporting obligation may be satisfied in the form of a joint report created by the Parties
following a JRC meeting, such joint report to reflect the information contained in Research Program updates made by the Parties at such JRC meeting along with supporting raw data. 

2.4 Subcontracting. ACI may use CROs or research institutions to outsource some of its activities under the Research Plan provided that
ACI shall delegate such responsibilities to CROs or research institutions in writing. All individual contractors or consultants performing any of ACI’s activities under a Research Plan must have entered into a written agreement with ACI that
includes terms and conditions protecting and limiting use and disclosure of Confidential Information and Know-How to the same extent as under this Agreement, and requiring all such individuals to assign to ACI all right, title and interest in and to
any intellectual property (and intellectual property rights) created, discovered, conceived or reduced to practice in conducting such activities. ACI is responsible for compliance by 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	11

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 
CROs, research institutions and Third Party FTEs with the terms and conditions of this Agreement as if those CROs, research institutions and Third Party FTEs were ACI’s employees. 

2.5 Research Costs. During the Research Term, each Party shall perform, at its expense, those activities to be undertaken by such Party
as set forth in the Research Plan. 
 2.6 Research Term. The Research Term commences as of the Effective Date and, unless the
Agreement is earlier terminated under Article 9, or the Research Program is earlier terminated under Section 14.1, shall continue until either (a) Genentech notifies ACI of termination of the Research Term at any time following the [*****]
of the Effective Date or (b) ACI notifies Genentech of termination of the Research Term at any time following the earlier of (i) the date on which the first Therapeutic Product is administered to the first human subject in a Phase I
Clinical Trial, or (ii) [*****] years after the Effective Date. After [*****] months following the end of the Research Term, the JRC is no longer required to meet. 

ARTICLE 3: DEVELOPMENT AND COMMERCIALIZATION EFFORTS 

3.1 Development and Commercialization Responsibilities. 

3.1.1 Exclusive Genentech Right. Except for those activities set forth in the Research Plan, as between the Parties, Genentech (and, if
applicable, Genentech Licensees) have the sole right and responsibility for, and control over, all research, development, manufacturing and commercialization activities, including all regulatory activities, with respect to any Licensed Products.

 3.1.2 Development Costs. Except as otherwise agreed to by the Parties, [*****] shall bear all costs and expenses associated with
research, development, manufacturing and commercialization activities with respect to Licensed Products, excluding costs incurred by [*****] in performance of its activities under the Research Plan. 

3.1.3 ACI Cooperation. ACI shall, and shall cause its employees, contractors and agents to, cooperate with and provide reasonable
support and assistance to Genentech in its conduct of any activities in the research, development, manufacturing and commercialization, including in the seeking of Marketing Approval, of Licensed Products. [*****] shall [*****] for any [*****]
reasonably incurred by [*****] in connection with such cooperation and support provided that such [*****] are approved in advance by [*****]. 

3.1.4 Development Updates. Throughout the Term, Genentech shall provide to ACI periodic updates on the plan for development of Licensed
Products containing ACI Antibody(ies) or Program Antibody(ies) under this Agreement on at least a [*****] basis. Such updates to include a summary of any significant progress or advances along with a general description of Genentech’s then-current plan of development. It is understood and agreed that the development plan summaries provided under this Section 3.1.4 are non-binding and provided to ACI for informational purposes only.

 3.2 Genentech Diligence. Genentech shall use Commercially Reasonable Efforts to develop and commercialize at least one Licensed
Product (other than a Diagnostic Product) for Alzheimer’s disease [*****] as indicated by compelling biologic rationale and commercial viability, and one Diagnostic Product for Alzheimer’s disease (whereby the failure to use Commercially
Reasonable Efforts to develop a Diagnostic Product only entitles ACI to pursuant to Section 9.2.1 partially terminate the license for Diagnostic Products). Activities by Genentech Licensees and Affiliates

  
  

			
	Research Collaboration and License Agreement (Tau)	  	12

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 
will be considered as Genentech’s activities under this Agreement for purposes of determining whether Genentech has complied with its obligations under this Section 3.2. 

3.3 Development of Licensed Products. 

3.3.1 Generally. The Parties intend and agree that filing for any Marketing Approval and commercialization of Licensed Products shall be
controlled by Genentech. Without limiting the generality of the foregoing, Genentech shall be responsible for making and have authority to make all decisions, and undertake any actions necessary as a result of such decisions, regarding development
(including additional preclinical and clinical development and testing), selecting drug candidates and preparing and filing BLAs and any other applications for Marketing Approval. Genentech shall own all regulatory submissions, including all
Marketing Approvals and applications therefor, for Licensed Products in the United States. 
 3.3.2 Cooperation. ACI shall cooperate
with and provide reasonable support to Genentech in its conduct of any activities in the development and seeking of Marketing Approval of Licensed Products. Without limiting the generality of the foregoing, ACI shall assist Genentech and any
Genentech Licensee in the preparation and filing of any applications for Marketing Approval with respect to Licensed Products, including by delivering all information in ACI’s Control (in a complete and accurate form) necessary or useful to
complete and file any Marketing Approval for a Licensed Product in the United States. [*****] shall [*****] for any [*****] reasonably incurred by [*****] in connection with such cooperation and support provided that such [*****] are approved in
advance by [*****]. 
 3.3.3 Transfer of Information and Regulatory Filings. Within [*****] days following the Effective Date and on
an ongoing basis during the Term, ACI agrees to transfer to Genentech all Know-How, including any preclinical data, assays and associated materials, protocols, reports, procedures and any other information in ACI’s Control, necessary or useful
to continue or initiate pre-clinical or clinical development, or in seeking Marketing Approval, of Licensed Products. 
 3.3.4
Manufacturing and Supply. Genentech shall be responsible for manufacturing and supplying Licensed Products for clinical use and commercial sale in the Genentech Field. 

ARTICLE 4: LICENSE GRANTS, NEGOTIATION RIGHT 

4.1 License Grants to Genentech. 

4.1.1 Therapeutic License. ACI hereby grants to Genentech, and Genentech hereby accepts an exclusive (even as to ACI) right and license
under the ACI IP Rights, the ACI Program IP Rights and ACI’s interest in the Joint Program IP Rights to research, develop, make, have made, use, sell, offer for sale and import Tau-Active Antibodies and Licensed Products in each case for use in
the Therapeutic Field in the Territory. The license granted to Genentech in this Section 4.1.1 shall include the right to sublicense to multiple tiers of Third Parties in accordance with the terms of Section 4.6. 

4.1.2 Diagnostic License. ACI hereby grants to Genentech, and Genentech hereby accepts an exclusive (even as to ACI) right and license
under the ACI IP Rights, the ACI Program IP Rights and ACI’s interest in the Joint Program IP Rights to research, develop, make, have made, use, sell, offer for sale and import Tau-Active Antibodies and Licensed Products for use in the
Diagnostic Field in the Territory. The license granted to Genentech in this Section 4.1.2 shall include the right to sublicense to multiple tiers of Third Parties in accordance with the terms of Section 4.6. 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	13

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 4.1.3 For the avoidance of doubt, no license is granted to Genentech to make, use, sell,
offer for sale or import [*****], provided however that nothing in this Section 4.1.3 shall limit Genentech’s right to make any biological materials for use in the research and development of Licensed Products. 

4.2 License Grant to ACI for Conduct of the Research Program. Subject to the terms of this Agreement, Genentech hereby grants to ACI a
non-exclusive, non-transferable, non-sublicenseable (except as expressly provided in Section 2.4), right and license under the (i) ACI IP Rights (to the extent exclusively licensed to Genentech hereunder), (ii) ACI Program IP Rights
and ACI’s interest in the Joint Program IP Rights (each to the extent exclusively licensed to Genentech hereunder), and (iii) Genentech IP Rights, in each case to research, develop, make and use (but not to sell or offer for sale)
Tau-Active Antibodies solely to the extent necessary for ACI to conduct those activities specified in the Research Plan or to otherwise generate and develop Discovery Antibodies for use or inclusion in the Research Program. 

4.3 Exclusivity; Restrictions. 

4.3.1 ACI shall not (i) provide any Tau-Active Antibodies or Licensed Products to any Third Party; or (ii) provide to any Third Party
any methods of screening for, identifying or making any Tau-Active Antibodies or Licensed Products, except as expressly provided in, and in strict accordance with, Section 2.4. For clarity, the foregoing restriction will not apply to
limit ACI’s use or transfer of Tau-Active Antibodies and related methods of screening, identification or manufacture, with respect to ACI’s activities outside the Genentech Field, including without limitation the research, development and
commercialization of Vaccine Products. 
 4.3.2 During the Term, the Parties agree that Genentech shall have the sole right to develop and
commercialize Tau-Active Antibodies and ACI shall not have any rights to develop or commercialize products containing Tau-Active Antibodies for any purpose. 

4.3.3 Academic Research. ACI may provide Tau-Active Antibody material existing prior the Effective Date to Katholieke Universiteit
Leuven (“K.U. Leuven”) solely for use in the academic research performed under the agreement entered into between ACI and K.U. Leuven effective as of July 1, 2008 (the “K.U. Leuven Agreement”) provided,
however, that (i) use of such Tau-Active Antibodies shall not conflict with Genentech’s exclusive rights under this Agreement; and (ii) all intellectual property rights (including but not limited to Patents and Know-How) made pursuant
to the K.U. Leuven Agreement shall be included within the ACI IP Rights to the extent necessary or useful to Genentech in exercising its rights under the licenses granted in this Agreement. 

4.3.4 Leuven License. ACI has provided to Genentech a true and correct copy (except for redactions of financial terms) of that certain
License Agreement between ACI and K. U. Leuven dated September 22, 2010 (the “Leuven License”). Genentech acknowledges that Leuven retained certain rights as set forth in the License Agreement and ACT has certain obligations
owed to Leuven and that the rights granted under this Agreement are subject to those retained rights and obligations. ACI shall not commit any acts or omissions that could cause a material breach of the Leuven License, such that K. U. Leuven would
be entitled to terminate the Leuven License or amend it in any way that would adversely affect a license or other rights granted to GNE under this Agreement. In addition, (i) without the prior written consent of GNE, ACI shall not exercise any
rights it may have with respect to the Leuven License or amend, terminate, or waive any of its rights under, the Leuven License in any way that would adversely affect a license or other rights granted to GNE under this Agreement and (ii) ACI
agrees to promptly notify GNE in the event that ACI receives notice of any alleged breach of the Leuven License or otherwise has reason to believe such an allegation is likely. ACI agrees that GNE may take any action

  
  

			
	Research Collaboration and License Agreement (Tau)	  	14

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

 

 
necessary to remedy any actual or alleged breach of the Leuven License where such action does not relieve ACI from any obligation hereunder. 

4.4 No Implied Licenses. Each Party acknowledges that the licenses granted under this Article 4 are limited to the scope expressly
granted, and all other rights under a Party’s Patents and other intellectual property rights are expressly reserved to the granting Party. 

4.5 Right of First Negotiation. Promptly following the Effective Date, ACI shall provide to Genentech all information in ACI’s
Control as reasonably necessary or useful for Genentech to evaluate its interest in the Vaccine Product Rights (including information and data regarding safety, efficacy, toxicity, potential side effects and any and all Marketing Approval filings).
Genentech shall have [*****] calendar days from receipt of such notice to notify ACI of Genentech’s intent to negotiate for the Vaccine Product Rights. Upon receipt by ACI of Genentech’s notice of intent to negotiate, ACI shall negotiate
solely and in good faith with Genentech for a period of [*****] calendar days (the “ROFN Period”). If the Parties are unable to agree on substantive terms within the ROFN Period, Genentech shall promptly reduce to writing its last
offer to ACI and provide such writing to ACI, and ACI shall be free to enter into an agreement with a Third Party for the sale or licensing of the ACI Vaccine Rights provided that the terms of such agreement when taken as a whole shall be no more
favorable to the Third Party than those last offered by Genentech. If ACI is unable to enter into an agreement with a Third Party on terms that are not more favorable to the Third Party than those terms last offered by Genentech and ACI notifies
Genentech of ACI’s desire to resume negotiations, the Parties agree to negotiate in good faith to reach a definitive agreement on mutually acceptable terms. 

4.6 Sublicenses. Genentech may sublicense its rights under the license set forth in Section 4.1, provided that any such
sublicense agreement is consistent with the terms and conditions of this Agreement. In the event of any such sublicense, Genentech shall continue to remain primarily liable for all liabilities and obligations under this Agreement, including the
payment obligations set forth in Article 5. Genentech is responsible for compliance by Genentech Licensees with the terms and conditions of this Agreement and the applicable sublicense agreement, including the diligence obligations set forth
in Section 3.2. 
 ARTICLE 5: PAYMENTS 

5.1 Up-Front Payment. In consideration for the rights granted and promises made hereunder, including the license granted to Genentech
under the ACI IP Rights, Genentech shall, within thirty (30) days of the Effective Date, pay to ACI a one-time payment of seventeen million Swiss Francs (CHF 17,000,000). 

5.2 Therapeutic Product Milestone Payments. 

5.2.1 With respect to the first Therapeutic Product containing an ACI Antibody (including a Discovery Antibody) or a Program Antibody (each a
“Milestone Product”) to achieve the clinical development, Marketing Approval Filing, or First Commercial Sale milestones (each a “Milestone”) set forth below, within [*****] days of the first occurrence that each
such Milestone is achieved, Genentech shall pay ACI the amounts set forth herein below. 
 (a) fourteen million Swiss Francs (CHF
14,000,000) upon the earlier of (i) ED-Go Decision by Genentech for a Milestone Product or (ii) the date Genentech files an IND for a Milestone Product. As used herein, the term “ED-Go Decision” means the review and endorsement by
GNE’s Early Stage Portfolio Committee (or any equivalent or successor governance body of Genentech) of the following details for the applicable Milestone Product: (a) available efficacy, safety, and pharmacology data, (b) plan and timeline to
IND submission, (c) resources required for IND-enabling activities and (d) strategic context; 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	15

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

 

 (b) fourteen million Swiss Francs (CHF 14,000,000) upon commencement (i.e., first patient
dosed) of the first Phase I Clinical Trial for a Milestone Product; 
 (c) With respect to Alzheimer’s disease indication: 

 

	 	(i)	[*****] upon [*****]; 

  

	 	(ii)	[*****] upon [*****]; 

  

	 	(iii)	[*****] upon [*****]; 

  

	 	(iv)	[*****] upon [*****]; 

  

	 	(v)	[*****] upon [*****]; 

  

	 	(vi)	[*****] upon [*****]; 

  

	 	(vii)	[*****] upon [*****]; and 

  

	 	(viii)	[*****] upon [*****]. 

 (d) With respect to each of the first [*****] to achieve the
applicable Milestone: 
  

	 	(i)	[*****] upon [*****]; 

  

	 	(ii)	[*****] upon [*****]; 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	16

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

	 	(iii)	[*****] upon [*****]; 

  

	 	(iv)	[*****] upon [*****]; 

  

	 	(v)	[*****] upon [*****]; 

  

	 	(vi)	[*****] upon [*****]; 

  

	 	(vii)	[*****] upon [*****]; and 

  

	 	(viii)	[*****] upon [*****]. 

 5.3 Diagnostic Product Milestone Payments. Upon [*****],
Genentech shall pay ACI [*****]. Within [*****] days following the end of the first calendar year in which Diagnostic Net Sales for such calendar year equal or exceed [*****] Genentech shall pay ACI [*****]. 

5.4 Therapeutic Product Royalties. In consideration for the rights granted hereunder, in each calendar quarter during the Term of this
Agreement in which Genentech records Net Sales of a Therapeutic Product, royalties as follows: 
 5.4.1 For Net Sales of a Therapeutic
Product Covered by a Valid Patent Claim within the ACI IP Rights in the country of sale other than the Discovery Antibody IP Rights in such country, and subject to and in accordance with the terms and conditions of this Agreement, Genentech shall
pay to ACI, on a Therapeutic Product-by-Therapeutic Product and country-by-country basis, an amount equal to [*****] of such annual Net Sales. 

5.4.2 For Net Sales of a Therapeutic Product Covered by the Discovery Antibody IP Rights in the country of sale and not Covered by any other
Valid Patent Claim within the ACI IP Rights in such country, and subject to and in accordance with the terms and conditions of this Agreement, Genentech shall pay to ACI, on a Therapeutic Product-by-Therapeutic Product and country-by-country basis,
an amount equal to [*****] of such annual Net Sales. 
 5.4.3 For Net Sales of a Therapeutic Product Covered by a Valid Patent Claim within
the ACI Program IP Rights or ACI’s interest in the Joint Program IP Rights in the country of sale (and not covered by a Valid Patent Claim within the ACI IP Rights), and subject to and in accordance with the

  
  

			
	Research Collaboration and License Agreement (Tau)	  	17

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 
terms and conditions of this Agreement, Genentech shall pay to ACI, on a Therapeutic Product-by- Therapeutic Product and country-by-country basis, an
amount equal to [*****] of such annual Net Sales. 
 5.4.4 For Net Sales of Therapeutic Products that contain as an active ingredient a
Tau-Active Antibody that is (i) an ACI Antibody or (ii) is generated by Genentech using proprietary screening technology within the ACI IP Rights and such Therapeutic Product is not Covered by a Valid Patent Claim within the ACI IP Rights
(including the Discovery Antibody IP Rights), the ACI Program IP Rights or the Joint Program IP Rights in the country of sale, a royalty equal to [*****] of annual Net Sales, provided, however, that royalty payment obligations under this
Section 5.4.4 shall terminate, on a country-by-country basis, upon the date that is [*****] years from the date of First Commercial Sale of the applicable Therapeutic Product in a country. For the sake of clarity, royalties paid under this
Section 5.4.4 shall be mutually exclusive of royalties to be paid under Sections 5.4.1-5.4.3; in no event shall royalties be paid under this Section 5.4.4 on Net Sales of Therapeutic Products Covered by a Valid Patent Claim
of the ACI IP Rights for which the royalty is paid under Section 5.4.1 or 5.4.2 or of the ACI Program IP Rights or Joint Program IP Rights for which a royalty is paid under 5.4.3. 

5.5 Diagnostic Product Royalties. In consideration for the rights granted hereunder, in each calendar quarter during the Term of this
Agreement in which Genentech records Diagnostic Net Sales of a Diagnostic Product Covered by a Valid Patent Claim within the ACI IP Rights, the ACI Program IP Rights or the Joint Program IP Rights in the country of sale, and subject to and in
accordance with the terms and conditions of this Agreement, Genentech shall pay to ACI, on a Diagnostic Product-by- Diagnostic Product and country-by-country basis, an amount equal to [*****] of such annual
Diagnostic Net Sales. 
 5.6 Timing of Payments. All payments due under Sections 5.4 and 5.5 shall be paid in quarterly installments
and be paid within [*****] days following the end of each calendar quarter. 
 5.7 Deductions from Payments. 

5.7.1 If in Genentech’s reasonable business judgment it is necessary to obtain a license under a issued patent of a Third Party in
connection with the research, development, manufacture, distribution, use, sale, import or export of a Therapeutic Product, [*****], including fee, royalty or other payment, against the royalties payable pursuant to Section 5.4.1 –
5.4.3 above; provided, that [*****]. 
 5.7.2 If in Genentech’s reasonable business judgment it is necessary to obtain a license
under any Blocking Third Party Intellectual Property in connection with the research, development, manufacture, distribution, use, sale, import or export of a Diagnostic Product, [*****], including fee, royalty or other payment, against the
royalties payable pursuant to Section 5.5 above; [*****] shall be in addition to, and not in lieu of, any other rights or claims Genentech may have under this Agreement or otherwise. For the purposes of this Section 5.7.2,
“Blocking Third Party Intellectual Property” means, with respect to any country in the Territory, Patent rights in such country owned or controlled by a Third 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	18

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 Party that cover specific reagents, assays and/or platform or any other technology required for use or sale
of a Diagnostic Product, if the manufacture, use or sale of such Diagnostic Product would in the absence of a license granted by such Third Party, infringe such Patent rights. 

5.7.3 For clarity, in no event will royalties payable on Therapeutic Products pursuant to Section 5.4 be reduced below a rate of
[*****] of annual Net Sales. 
 5.8 Additional Royalty Terms. 

5.8.1 Single Royalty. Notwithstanding anything herein to the contrary, with respect to any Licensed Product only a single royalty
payment shall be due and payable, regardless if such Licensed Product is covered by more than one Valid Patent Claim or contains more than one component Covered by a Valid Patent Claim. 

5.8.2 Royalty Term; Fully Paid Licenses. Where tied to a Valid Patent Claim, royalties under this Article 5 are payable only
during time periods in which sale of the applicable Licensed Product is Covered by a Valid Patent Claim in the applicable country. Upon expiration of the obligation to pay royalties for a particular Licensed Product in a given country under
Section 5.4 and Section 5.5, the licenses granted to the Party under this Agreement with respect to such Licensed Product in such country shall become fully paid and irrevocable. 

ARTICLE 6: REPORTS, AUDITS AND FINANCIAL TERMS 

6.1 Reports. 
 6.1.1
Royalty Reports. Within [*****], Genentech shall send to ACI a report of Net Sales of the Licensed Products for which a royalty is due, which report sets forth for such calendar quarter the following information: (i) total Net Sales of
all Licensed Products sold in the Territory during such calendar quarter, (ii) the exchange rate used to convert Net Sales from the currency in which they are earned to Swiss Francs (CHF), (iii) Net Sales on a country-by-country basis for
each of [*****] and (iv) the total royalty payments due. 
 6.2 Additional Financial Terms. 

6.2.1 Currency. All payments to be made under this Agreement shall be made in Swiss Francs (CHF). Amounts invoiced in a currency other
than Swiss Francs must be expressed in the Swiss Francs (CHF) equivalent as well as any local currency. Net Sales shall be first determined in the currency in which they are earned and shall then be converted into an amount in Swiss Francs (CHF).
All currency conversions shall use the conversion rate used by Roche for its then-current external reporting requirements, consistently applied. 

6.2.2 Payment Type. Amounts paid by one Party to the other under this Agreement shall be paid in Swiss Francs (CHF), in immediately
available funds, by means of wire transfer to an account identified by the payee. 
 6.2.3 Withholding of Taxes. Each Party may
withhold from payments due to the other Party amounts for payment of any withholding tax that is required by law to be paid to any taxing authority with respect to such payments. The Party withholding the tax shall provide to the other Party all
relevant documents and correspondence, and shall also provide to the Party from whose payment that tax 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	19

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 was withheld any other cooperation or assistance on a reasonable basis as may be necessary to enable that
Party subject to withholding to claim exemption from such withholding taxes and to receive a full refund of such withholding tax or claim a foreign tax credit. The Party withholding the tax shall give proper evidence from time to time as to the
payment of such tax. The Parties shall cooperate with each other in seeking deductions under any double taxation or other similar treaty or agreement from time to time in force. Such cooperation may include Genentech making payments from a single
source in the U.S., where possible or Switzerland. 
 6.2.4 Late Payments. Any amounts not paid within [*****] days after the date
due under this Agreement are subject to interest from the date due through and including the date upon which payment is received. Interest is calculated, over the period between the date due and the date paid, at a rate equal to [*****]. 

6.2.5 Blocked Currency. If, at any time, legal restrictions prevent the prompt remittance of part or all royalties with respect to any
country where a Licensed Product is sold, payment shall be made through such lawful means or methods as the Party paying may determine. When in any country, the law or regulations prohibit both the transmittal and deposit of royalties or other
payments, the Party paying shall continue to report all such amounts, but may suspend payment for as long as such prohibition is in effect. As soon as such prohibition ceases to be in effect, all amounts that would have been obligated to be
transmitted or deposited, but for the prohibition, shall forthwith be deposited or transmitted promptly. 
 6.3 Accounts and Audit.

 6.3.1 Records. Each Party shall keep full, true and accurate books of account containing the particulars of Net Sales, the
calculation of royalties. Each Party shall keep such books of account and the supporting data and other records. Such books and records must be maintained available for examination in accordance with this Section for [*****] calendar years after the
end of the calendar year to which they pertain, and otherwise as reasonably required to comply with IFRS. 
 6.3.2 Appointment of
Auditor. Each Party may appoint an internationally-recognized independent accounting firm reasonably acceptable to the audited Party to inspect the relevant books of account of the audited Party to verify any reports or statements provided, or
amounts paid or invoiced (as appropriate), by that audited Party. The independent accounting firm (and any individuals, if applicable) appointed to perform the examination under this Agreement must execute a confidential disclosure agreement with
the audited Party, or otherwise be subject to terms governing non-use and non-disclosure of information that the audited Party has agreed in writing are acceptable. 

6.3.3 Procedures for Audit. Each Party may exercise its right to have the other Party’s relevant records examined only during the
[*****] year period during which the audited Party is required to maintain records, no more than once in any consecutive [*****] calendar quarter period, and only once with respect to records covering any specific period of time. The audited Party
is required to make its records available for inspection only during regular business hours, only at such place or places where such records are customarily kept, and only upon receipt of at least [*****] days written advance notice from the other
Party. 
 6.3.4 Audit Report. The independent accountant will be instructed to provide an audit report containing its conclusions
regarding the audit, and specifying whether the amounts paid were correct, and, if incorrect, the amount of any underpayment or overpayment. The independent accountant further will be instructed to provide that audit report first to the audited
Party, and will be further instructed to redact any proprietary information of the audited Party not relevant to the calculation of 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	20

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 
royalties prior to providing that audit report to the other Party. That audit report shall be deemed to be Confidential Information of the audited Party, and used only for purposes germane to
this Section. 
 6.3.5 Underpayment and Overpayment. After review of the auditor’s report: (i) if there is an uncontested
underpayment by the audited Party for the period in question, then the audited Party shall pay to the other Party the full amount of that uncontested underpayment, and (ii) if there is an uncontested overpayment by the audited Party for the
period in question, then the other Party shall provide to the audited Party a credit against future payments (such credit equal to the full amount of that overpayment), or, if the audited Party is not obligated to make any future payments, then the
other Party shall pay to the audited Party the full amount of that overpayment. Contested amounts are subject to dispute resolution under Article 13. If the total amount of any underpayment (as agreed to by the audited Party or as determined
under Article 13) exceeds [*****] of the amount previously paid by the audited Party for the period subject to audit (as long as that period is at least [*****] consecutive calendar quarters), then the audited Party shall pay the reasonable
costs for the audit. 
 6.4 Rights Regarding Consolidation of ACI Financial Data. If, at any time during the term of this Agreement,
compliance with any term or condition of this Agreement would, in Genentech’s opinion and with the concurrence of Genentech’s independent auditors, require Genentech to consolidate ACI within Genentech’s financial statements in order
to comply with Accounting Standards in effect at that time, then upon Genentech’s request, ACI shall provide to Genentech (a) ACI’s unaudited quarterly consolidated financial statements, prepared in accordance with IFRS (i.e., balance
sheet, income statement and statement of cash flows) for each calendar quarter within [*****] days after the end of the calendar quarter, and (b) subject to the obligations under Article 12 regarding Confidential Information, ACI’s
forecasted results for a given calendar quarter, based on its best available estimates, no earlier than [*****] days prior to, and no later than [*****] days prior to, the close of such calendar quarter. Those forecasted results must be based on at
least [*****] months of actual results and will encompass all of the financial statements noted above. 
 ARTICLE 7: INTELLECTUAL
PROPERTY; PATENT PROSECUTION AND MAINTENANCE 
 7.1 Disclosure of Inventions. 

7.1.1 ACI shall promptly disclose to GNE any inventions or other Know-How created, discovered, conceived or reduced to practice pursuant to the
Research Program and the activities in the Research Plan. During the Research Term and the remainder of the Term of the Agreement, ACI shall disclose to GNE all Patents within ACI IP Rights and Program IP Rights (including in each case, any such
Patents of which ACI acquires Control after the Effective Date). 
 7.1.2 Promptly after the Effective Date, ACI shall deliver to GNE copies
of all patent applications, amendments, correspondence with patent offices and information relating to Patents within the ACI IP Rights. ACI shall timely deliver to GNE within [*****] days of its receipt, copies of any patent applications,
amendments, correspondence or other materials that ACI receives following the Effective Date from the U.S. Patent and Trademark Office and all other patent offices relating to the Patents within the ACI IP Rights. 

7.2 Ownership of IP Rights. 

7.2.1 Program IP Rights. As between the Parties, (i) Program IP Rights that are invented by employees of ACI solely (or jointly
with a Third Party subcontractor of ACI) (“ACI Program IP Rights”) will be solely owned by ACI; (ii) Program IP Rights that are invented by employees of Genentech solely (or jointly with a Third Party subcontractor of
Genentech) (“Genentech Program IP 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	21

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 
Rights”) will be solely owned by Genentech; and (iii) Program IP Rights that are invented by an employee of Genentech (or a Third Party subcontractor of Genentech) and an
employee of ACI (or a Third Party subcontractor of ACI) jointly (“Joint Program IP Rights”) will be jointly owned by Genentech and ACI. Inventorship for purposes of determining ownership under this Section is determined under
Section 7.6. 
 7.2.2 Joint Ownership. Each Party retains an undivided one-half interest in and to Joint Program IP
Rights. ACI shall exercise its ownership rights in and to Joint Program IP Rights, for any field, and including the right to license and sublicense or otherwise to exploit, transfer or encumber its ownership interest, only (i) with prior
written consent of Genentech, not to be unreasonably withheld; (ii) subject to the licenses under this Agreement; and (iii) in accordance with the restrictions set forth in Section 4.3. Notwithstanding the foregoing, solely
with respect to (a) improvements made by the Parties in the performance of activities under the Research Plan to techniques and/or methods consisting of assays, detection methods and screening methods within the ACI IP Rights existing as of the
Effective Date and (b) such other techniques and/or methods consisting of assays, detection methods and screening methods made by the Parties in the performance of activities under the Research Plan (together, the
“Improvements”), ACI may freely exploit Joint Program IP Rights that constitute Improvements for uses outside the Genentech Field without obtaining Genentech’s prior consent. This Agreement shall be understood to be a joint
research agreement in accordance with 35 U.S.C. § 103(c) to develop Tau-Active Antibodies for use in and outside the Genentech Field, provided that neither Party shall be required by this reference to have any Patent take advantage of or become
subject to such § 103(c) except in accordance with the provisions of this Article 7 regarding Prosecution and Maintenance of such Patent. 

7.3 Assignments. 
 7.3.1
Genentech. Genentech shall require all of its employees, contractors and agents, and any Affiliates and Third Parties working on its behalf under this Agreement (and their respective employees, contractors and agents), to assign to Genentech
any Program IP Rights and Genentech IP Rights, created, discovered, conceived or reduced to practice by such employees, contractors or agents or Affiliates or Third Parties. 

7.3.2 ACI. ACI shall require all of its employees, contractors and agents, and any Affiliates and Third Parties working on its behalf
under this Agreement (and their respective employees, contractors and agents), to assign to ACI any Program IP Rights and ACI IP Rights, created, discovered, conceived or reduced to practice by such employees, contractors or agents or Affiliates or
Third Parties. 
 7.3.3 Cooperation. The Parties shall cooperate with each other to effectuate ownership of any intellectual property
rights as set forth in this Agreement, including, but not limited to, by executing and recording documents. 
 7.4 Patent Prosecution and
Maintenance. 
 7.4.1 Definition. For purposes of this Section 7.4.1, “Prosecution and Maintenance” or
“Prosecute and Maintain,” with regard to a particular Patent, means the preparation, filing, prosecution and maintenance of such Patent, as well as re-examinations, reissues, applications for patent term extensions and the like with
respect to that Patent, together with the conduct of interferences, the defense of oppositions and other similar proceedings with respect to that Patent. 

7.4.2 Genentech Controlled Prosecution and Maintenance. As between the Parties, Genentech shall, at its sole discretion and expense,
have the right (but not the obligation) to Prosecute and 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	22

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 
Maintain Patents within the Genentech IP Rights, but excluding [*****] and [*****]. 

7.4.3 Prosecution and Maintenance of ACI IP Rights and Program IP Rights. Subject to the provisions of this Section and
Section 7.4.5, ACI and Genentech shall select a mutually agreeable outside counsel (“Outside Patent Counsel”) to be responsible for the Prosecution and Maintenance of ACI IP Rights and Program IP Rights. 

(a) Cooperation. With respect to Patents within the ACI IP Rights and Program IP Rights, the Parties shall cooperate and assist each
in the Prosecution and Maintenance of such Patents as set forth below and in Section 7.4.4. 
 (b) As soon as one of the
Parties determines that it wishes to file a patent application covering any such invention within the ACI IP Rights or Program IP Rights, it shall promptly inform the other Party thereof. With respect thereto, the Parties shall promptly engage the
Outside Patent Counsel to draft a patent application for such invention and to make a preliminary determination of inventors, and scope of claims. The Parties shall instruct the Outside Patent Counsel to provide to each Party a copy of such patent
application for review and comments by the Parties, and such Outside Patent Counsel shall be instructed to reasonably consider the comments of both Parties. 

(c) The Outside Patent Counsel shall be instructed to (i) keep the Parties informed as to the filing, and Prosecution and Maintenance
(including those involving in which countries to initiate or continue prosecution (including validation), the question of the scope of, the issuance of, the rejection of, an interference involving, or an opposition to any such patent application or
resulting Patent) of, such Patents, such that each Party has sufficient time to review and comment upon any documents intended for submission to any patent office; (ii) furnish to each Party a copy of the patent application and copies of
documents relevant to such Prosecution and Maintenance, including copies of correspondence with any patent office, foreign associates, and outside counsel; and (iii) reasonably consider and incorporate comments of the Parties on documents filed
with any patent office. In addition, the Outside Patent Counsel shall provide the Parties with a report, no less frequently than once per calendar quarter (or as otherwise mutually agreed by the Parties), listing all Patents within ACI IP Rights and
Program IP Rights, identifying them by country and patent or application number, and briefly describing the status thereof. 
 (d) The
Outside Patent Counsel shall be instructed to advise and consult with each Party promptly after receiving any substantial action or development in the prosecution of any patent application it is responsible for prosecuting pursuant to
Section 7.4.3(a) (in particular any actions or developments concerning in which countries to initiate or continue prosecution (including validation), questions of the scope, issuance or rejection of, any interference involving, any such
patent application or any opposition to any such patent application or resulting patent). 
 7.4.4 Consultation and Cooperation.
Generally, the Parties shall cooperate with and assist each other in the Prosecution and Maintenance of Patents within the ACI IP Rights and Program IP Rights, including (i) consulting with the other Party promptly after receiving any
substantial action or development in the prosecution of any such Patent, (ii) making scientists and scientific records reasonably available in connection with such Prosecution and Maintenance, and (iii) making reasonably available its
respective authorized attorneys, agents or representatives. In addition, each Party shall sign or use its best efforts to have signed and delivered, at no charge to the other Party, all documents necessary in connection with such Prosecution and
Maintenance. 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	23

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 7.4.5 Abandonment of Prosecution and Maintenance. With respect to Patents within the
ACI IP Rights and Program IP Rights, if a Party (the “Electing Party”) elects not to Prosecute and Maintain such Patents (whether worldwide or with respect to any particular country), including electing not to file a patent
application with respect thereto or to allow any such Patents to lapse or become abandoned or unenforceable, then the Electing Party shall promptly notify the other Party (the “Non- Electing
Party”) in writing (which such notice shall be at least [*****] days prior to the lapse or abandonment of any such Patent). Thereafter, the Non-Electing Party may, but is not required to, undertake, at its sole expense and in its sole
discretion, the Prosecution and Maintenance of such Patents. In the event that the Non-Electing Party undertakes such Prosecution and Maintenance, (i) the Electing Party shall assign all right, title and interest in and to such Patents to the
Non-Electing Party, (ii) Electing Party shall cooperate as set forth in Section 7.4.4, and (iii) notwithstanding anything in this Agreement to the contrary, such Patents shall no longer serve as the basis of any royalty
obligation to the Electing Party under this Agreement. 
 7.4.6 Costs. Unless otherwise mutually agreed by the Parties, both during
and after the Term of this Agreement, all costs of prosecuting and maintaining Genentech IP Rights shall be Genentech’s sole responsibility. Genentech shall bear [*****] of the costs of prosecuting and maintaining all ACI IP Rights and Program
IP Rights and ACI shall bear [*****] of such costs. 
 7.4.7 Good Faith. Without in any way limiting the foregoing, including
Section 7.4.3(a), the Parties shall use reasonable efforts and act in good faith to assist and advise the other and the Outside Patent Counsel in connection with the Prosecution and Maintenance of Patents within the ACI IP Rights and
Program IP Rights, and to mutually seek opportunities to prepare and file patent applications for such Patents, [*****]. 
 7.5 Patent
Interferences. If an interference is declared by the U.S. Patent and Trademark Office (a) between (i) a claim in one or more Patents within the ACI IP Rights or Program IP Rights and (ii) a claim in one or more Patents within the
Genentech IP Rights, where at least one of such claims would, but for the licenses in this Agreement, be infringed by the making, using, offering for sale, selling or importing of a Tau-Active Antibody or Licensed Product; then the Parties shall in
good faith establish within [*****] days of the declaration of such interference, or such other time as agreed upon, a mutually agreeable process to resolve such interference in a reasonable manner (including control and cost sharing), in
conformance with all applicable legal standards. 
 7.6 Inventorship. Any determination of inventorship with respect to any Patent
within the ACI IP Rights, Program IP Rights, or Genentech IP Rights shall be made in accordance with the applicable United States patent laws. 

7.7 Consequences of [*****]. 

7.7.1 Termination on [*****]. ACI shall have the right to terminate this Agreement, to the extent permitted by applicable law and
regulation, by written notice effective upon receipt by Genentech if Genentech or its Affiliates directly, or indirectly through material assistance knowingly granted to a Third Party, makes, files or maintains any claim, demand, lawsuit or cause of
action to [*****] of, or [*****], in each case with respect to any [*****] (each such action a “[*****]”). Prior to exercising such right, ACI shall first provide Genentech with written notice regarding the occurrence of any [*****]
(“Notice of [*****]”). Provided that (i) the [*****] is reversible, and (ii) Genentech is able to obtain a full and 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	24

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 complete withdrawal of the [*****] within [*****] days following Genentech’s receipt of the Notice of
[*****], and (iii) no substantial [*****] to the [*****] has been caused by the [*****] prior to such withdrawal, then ACT may not terminate this Agreement pursuant to this Section 7.7.1. For the avoidance of doubt, [*****] does not
include, and termination by ACI under this Section 7.7.1 is not permitted for, (i) any action undertaken by Genentech or its Affiliates in any [*****] if such [*****] was provoked, requested or otherwise commenced by a Third Party
without material assistance knowingly granted by Genentech or its Affiliates; (ii) any [*****] by Genentech or its Affiliates [*****] or other action made, filed or maintained by ACI, ACI’s Affiliate(s) and/or ACT Licensee(s), including
where such [*****] of or by any Genentech activity with respect to [*****], including without limitation any [*****] by Genentech or its Affiliates that the making, using, selling, offering for sale and importation of any [*****] and/or Licensed
Product(s) do not [*****] ACI IP Rights. 
 ARTICLE 8: ENFORCEMENT OF IP RIGHTS; DEFENSE OF THIRD PARTY 

INFRINGEMENT CLAIMS 
 8.1
Notice. Each Party shall promptly notify, in writing, the other Party upon learning of any actual or suspected infringement of the ACI IP Rights or Program IP Rights by a Third Party, or of any claim of invalidity, unenforceability, or
non-infringement of the ACI IP Rights or Program IP Rights, and shall, along with such notice, supply the other Party with all evidence in its possession pertaining thereto. In addition, ACI shall promptly notify Genentech, in writing, upon learning
of any actual or suspected infringement of the Genentech IP Rights by a Third Party, or of any claim of invalidity, unenforceability, or non-infringement of the Genentech IP Rights, and shall, along with such notice, supply Genentech with all
evidence in its possession pertaining thereto. 
 8.2 Infringement Action. 

8.2.1 Genentech IP Rights. As between the Parties, Genentech shall have at its own cost the sole right, but not the obligation, to seek
to abate any actual or suspected infringement of the Genentech IP Rights by a Third Party, or to file suit against any such Third Party. ACI shall cooperate with Genentech (as may be reasonably requested by Genentech), including, if necessary, by
being joined as a party. 
 8.2.2 ACI IP Rights and Program IP Rights. Genentech shall have at its own cost the first right, but not
the obligation, to seek to abate any actual or suspected infringement of the ACI IP Rights, ACI Program IP Rights and ACI’s interest in the Joint Program IP Rights by a Third Party, or to file suit against any such Third Party. If Genentech
does not commence an infringement action against the alleged or threatened infringement or otherwise seek to abate the infringement (which may include without limitation entering into a sublicense agreement with the infringer) by the earlier of
(a) [*****] months after ACI provides to Genentech written notice of such infringement or (b) [*****] Business Days before the time limit, if any, set forth in appropriate laws and regulations for filing of such actions, then ACI may
commence litigation with respect to the alleged or threatened infringement at its own expense; provided, that ACI shall not initiate such litigation if enforcement of such ACI IP Rights, ACI Program IP Rights or ACI’s interest in the Joint
Program IP Rights would have a material adverse effect on the development, commercialization, or commercial value of Licensed Products pursuant to this Agreement. 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	25

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 8.3 Settlement. [*****]. 

8.4 Damages. Unless otherwise mutually agreed by the Parties, and subject to the respective indemnity obligations of the Parties set
forth in Article 11, all monies recovered upon the final judgment or settlement of any action described in Section 8.2, shall be used: (i) first, to reimburse [*****], on a pro rata basis for its out-of-pocket expenses
relating to the action; (ii) second, any remaining balance that represents compensation for lost sales, a reasonable royalty or lost profits, shall be retained by or paid to [*****] subject to the payment of royalties on such amounts pursuant
to Article 5; and (iii) third, any remaining amount that represents additional damages (for example, enhanced or punitive damages) shall be retained by [*****]. 

8.5 Third Party Suits. In the event that a Third Party shall make any claim or bring any suit or other proceeding against [*****], or any of
its Affiliates, [*****] or customers, for infringement or misappropriation of any intellectual property rights with respect to the research, development, making, using selling, offering for sale, import or export of any Tau-Active Antibody or
Licensed Product, [*****] shall have the right to defend and control the defense of such claim, suit or other proceeding as well as to initiate and control any counterclaim or other similar action at its own cost and expense. [*****] shall fully
cooperate with [*****] in defense of such claim, suit or other proceeding, including by being joined as a party. Unless otherwise mutually agreed by the Parties, and subject to the respective indemnity obligations of the Parties set forth in
Article 11, the provisions of Sections 8.3 and 8.4 shall apply to any proceeding covered by this Section 8.5, except that the negotiation of any license from the Third Party shall be subject to Section 5.7. 

8.6 Genentech shall have the sole right, but not the obligation, to obtain and control, at its own expense and discretion, any data/marketing
exclusivity rights with respect to regulatory filings (including clinical, safety and efficacy data) with respect to Licensed Products including defense and enforcement of rights against Third Parties seeking marketing authorization approval from a
regulatory agency (including the FDA, EMA or equivalent) based on such filings. Such rights shall specifically include the right to take action in connection with Third Party applications for marketing authorization for biosimilar products or
generic products that reference any Licensed Product pursuant to Title VII of the United States Patient Protection and Affordable Care Act, Biologics Price Competition and Innovation Act, the Hatch-Waxman Act, EU Directive 2004/27/EC and any
successor legislation or regulations relating thereto, and all similar foreign legislation with regard to the foregoing. 
 ARTICLE 9:
TERM AND TERMINATION 
 9.1 Term. The term of this Agreement (the “Term”) shall commence on the Effective Date
and, unless sooner terminated by mutual agreement or pursuant to any other provision of this Agreement, shall terminate on the date on which all obligations under this Agreement between the Parties with respect to the payment of milestones or
royalties with respect to Licensed Products have passed or expired. 
 9.2 Termination. 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	26

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 9.2.1 Material Breach. Either Party may terminate this Agreement for any material
breach by the other Party, provided that the terminating Party gives the breaching Party written notice of such breach and the breach remains uncured after the expiration of [*****] days (or [*****] days if such breach relates solely to the payment
of amounts due hereunder) after such written notice was given. 
 9.2.2 Bankruptcy. Genentech shall have the right to terminate this
Agreement upon written notice to ACI, in the event that ACI seeks protection of any bankruptcy or insolvency law, a proceeding in bankruptcy or insolvency is filed by or against ACI and is not dismissed within [*****] days, or there is an
adjudication by a court of competent jurisdiction that ACI is bankrupt or insolvent. ACI shall have the right to terminate this Agreement upon written notice to Genentech, in the event that Genentech seeks protection of any bankruptcy or insolvency
law, a proceeding in bankruptcy or insolvency is filed by or against Genentech and is not dismissed within [*****] days, or there is an adjudication by a court of competent jurisdiction that Genentech is bankrupt or insolvent. 

9.2.3 Termination for Convenience. Genentech may terminate this Agreement at any time after the [*****] anniversary of the Effective
Date with or without cause, upon three (3) months advanced written notice to ACI. 
 9.2.4 Change of Control. Genentech may terminate
this Agreement in accordance with Section 14.3. 
 9.3 Effect of Termination or Expiration. 

9.3.1 Upon termination of this Agreement by ACI pursuant to Section 9.2.1 for material breach by Genentech of its diligence
obligations under Section 3.2, its payment obligations under Sections 5.1-5.5, or for a [*****] under Section 7.7.1 or by Genentech pursuant to Section 9.2.3, (i) all rights and licenses granted to
Genentech under Article 4 shall immediately terminate; (ii) upon request by ACI within the first [*****] months following the effective date of termination and subject to the Termination Royalties described in Section 9.4
below, Genentech shall provide a Product Reversion Package to ACI to support the continued development and commercialization of Termination Products and shall grant and hereby grants (effective only upon ACI’s request received within the
[*****] months following the effective date of termination in accordance with this Section 9.3.1) to ACI the license grant set forth in clause, (vi) of the Product Reversion Package definition; (iii) upon request by ACI,
Genentech shall continue to manufacture and supply to ACI for a period of [*****] years such Termination Products that are, as of the date of such termination, in clinical development or sold commercially, such supply to be reimbursed by [*****] at
a cost equal to [*****] fully burdened manufacturing cost plus [*****]. Any sublicense granted to a Genentech Licensee [*****] shall survive termination of this Agreement under this Section 9.3.1, provided that such Genentech Licensee
(i) is not, on the effective date of such termination, in [*****]; (ii) agrees, in a subsequent writing, to perform and deliver directly to [*****]; and (iii) agrees, in a subsequent writing, that, [*****]. 

9.3.2 Upon termination by Genentech pursuant to Section 9.2.1 for material breach by ACI, Section 9.2.2 or
Section 9.2.4, Genentech may elect, in its sole discretion, to terminate this 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	27

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 
Agreement in its entirety or to partially terminate this Agreement in accordance with the terms of Section 9.3.2 (a). 

(a) Partial Termination. Upon Genentech’s election to partially terminate this Agreement, (i) all rights and licenses
granted to ACI under Article 4 shall immediately terminate, (ii) the rights and obligations of the Parties under the following sections of this Agreement shall survive such termination: Articles 3 (except
Section 3.1.4), 4 (except Section 4.2), 5 , 6 (except Section 6.1.1), 7, 8, 9, 10, 11, 12, 13, and 14, but in all cases the surviving provisions shall be interpreted to exclude the subject matter of
non-surviving terms, and (iii) all Genentech Confidential Information, data and materials provided to ACI under this Agreement shall be returned to Genentech or destroyed, at Genentech’s option. 

(b) Partial Termination Upon Specific Breach Events. In the case that the ACI breach that gave rise to a partial termination of this
Agreement in accordance with Section 9.3.2(a) was a breach of any of the following provisions: Sections 2.3.2 (except to the extent that the breach of the provision by ACI is based on the unavailability of biological material due
to a scientific or technical obstacle, i.e., destruction of a cell line, not caused by the gross negligence or willful misconduct of ACI) and provided the breach is the consequence of gross negligence or willful misconduct of ACI, 3.1.1,
4.1, 4.3.1, 8.2, 10.1 (except Section 10.1.1(e)) or Article 12, then, (i) the surviving provision set forth in Section 9.3.2(a) shall be modified to provide that Section 3.2
will not survive such partial termination; (ii) upon the First Commercial Sale of a Licensed Product by Genentech, the payments made by Genentech under Sections 5.2 and 5.3 shall be creditable against royalty payments due to ACI under
Sections 5.4 and 5.5 subject to clause (c)(i) of this Section 9.3.2: and (iii) Genentech shall have no obligation to pay royalties on Net Sales of Licensed Product under Sections 5.4 or 5.5, subject to
clause (c)(ii) of this Section 9.3.2. 
 (c) Upon the First Commercial Sale of a Licensed Product by Genentech, ACI may
initiate an arbitration procedure under Section 13.2 for the limited determinations described in the following clauses (i) and (ii), in both cases where ACI has the burden of proof. 

(i) Milestone Offsets. If ACI establishes that the total damage amount suffered by Genentech resulting from ACI’s material breach
that was the basis of Genentech’s partial termination under Section 9.3.2(b) were less than the total of the milestone payments made to ACI under Sections 5.2 and 5.3, then Genentech shall only be entitled to credit such
total damage amount against royalty payments due to ACI under Sections 5.4 and 5.5. 
 (ii) Royalty. If ACI establishes that
the material breach that was the basis of Genentech’s partial termination under Section 9.3.2(b) did not have a material adverse effect on the value on the scope, validity or enforceability of the ACI IP Rights or the market
exclusivity granted by such rights, in each case in the Genentech Field, then notwithstanding clause (iii) of Section 9.3.2(b), Genentech’s obligation to pay royalties to ACI in accordance with Sections 5.4 or 5.5 shall
continue. 
 9.3.3 Termination or expiration of this Agreement, through any means and for any reason, shall not relieve the Parties of any
obligation accruing prior thereto, including the payment of all sums due and payable, and shall be without prejudice to the rights and remedies of either Party with respect to any antecedent breach of any of the provisions of this Agreement. 

9.4 Termination Financials. Subsequent to termination as described in Section 9.3.1 and in consideration of the data and
information provided to ACI by Genentech thereunder, the financial provisions of this Section 9.4 shall apply as follows: 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	28

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 9.4.1 In each calendar quarter in which ACI records Net Sales of a Termination Product, ACI
shall pay to Genentech, on a Termination Product-by-Termination Product and country-by-country basis, an amount equal to the amounts set forth in Sections 9.4.2-9.4.6 as follows: 

9.4.2 [*****] of annual Net Sales of Termination Products that are [*****] 

9.4.3 [*****] of annual Net Sales of Termination Products that are [*****] 

9.4.4 [*****] of annual Net Sales of Termination Products that are [*****] 

9.4.5 [*****] of annual Net Sales of Termination Products that are [*****] 

9.4.6 [*****] of annual Net Sales of Termination Products that are [*****] and 

9.4.7 For Net Sales of Termination Products not Covered by a Valid Patent Claim within the Genentech IP Rights in the country of sale, a
royalty equal to [*****] of the applicable royalty that would otherwise be payable under Sections 9.4.1-9.4.6, provided, however, that royalty payment obligations under this Section 9.4.7
shall terminate upon the date that is [*****] years from the date of First Commercial Sale of the applicable Termination Product in a country. For the sake of clarity, royalties paid under this Section 9.4.7 shall be mutually exclusive
of royalties to be paid under Sections 9.4.1-9.4.6; in no event shall royalties be paid under this Section 9.4.7 on Net Sales of Termination Products Covered by a Valid Patent Claim of the Genentech IP Rights. 

9.5 Survival. In addition to as set forth in Section 9.3 and otherwise explicitly set forth in this Agreement, Articles
1, 11, 12 and 13 and Sections 7.2, 7.3, 9.3, 9.4, 9.5 and 10.3, and, as applicable, Article 6 shall survive expiration or termination of this Agreement for any reason. 

ARTICLE 10: REPRESENTATIONS AND WARRANTIES 

10.1 ACI Representations. ACI hereby represents and warrants to Genentech that: 

10.1.1 As of the Effective Date, ACI represents that: 

(a) ACI has the full right, power and authority, and has obtained all approvals, permits or consents necessary, to enter into this Agreement
and to perform all of its obligations and to grant the licenses provided hereunder. 
 (b) No claims of infringement, misappropriation or
other conflict with any 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	29

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 intellectual property rights or other rights owned or controlled by any Third Party have been made or, to
ACI’s knowledge, threatened with respect to the ACI IP Rights existing as of the Effective Date. 
 (c) None of the ACI IP Rights
existing as of the Effective Date is subject to any outstanding injunction, judgment, order, ruling, or charge, and no claim or action is pending or, to ACI’s knowledge, threatened which challenges the legality, validity, enforceability, use,
or ownership of any such ACI IP Rights, and ACI is not aware of any facts or circumstances that indicate a likelihood of the foregoing. As of the Effective Date, no loss or expiration of any of the ACI IP Rights is threatened, pending, or reasonably
foreseeable, except for patents expiring at the end of their statutory terms (and not as a result of any act or omission by ACI, including a failure to pay any required maintenance fees). 

(d) ACI is not aware (without having made any specific inquiry) of any infringement or misappropriation of the ACI IP Rights existing as of
the Effective Date by any Third Party. 
 (e) ACI has, up through and including the Effective Date, made available to or provided Genentech
with copies of all material information and, as requested in writing by Genentech, with copies of all books, records and data, in each case with respect to the ACI IP Rights and ACI Antibodies, provided that this clause (e) is exclusive of
information that was excluded from disclosure under Paragraph 3 of the Mutual Confidentiality Agreement between the Parties dated March 18, 2010, as amended. 

10.1.2 ACI hereby represents and warrants to Genentech that as of the Effective Date and through out the Term: 

(a) ACI is the sole and exclusive owner of or Controls the ACI IP Rights existing as of the Effective Date free and clear of any liens or
encumbrances. 
 (b) ACI has not, prior to the Effective Date, entered into and shall not, following the Effective Date, enter into any
agreement and has not granted any now existing, or agreed to grant any future, license, right or privilege which would adversely affect the rights and licenses granted by ACI to Genentech pursuant to this Agreement. 

(c) The intellectual property rights licensed by ACI to Genentech pursuant to this Agreement constitute all Patents, Know-How and other
intellectual property rights that are owned or Controlled by ACI or its Affiliates and that (i) relate to Licensed Products and Tau-Active Antibodies or (ii) are conceived, reduced to practice or otherwise created by ACI during the conduct
of or in connection with activities under the Research Program. 
 (d) ACI follows reasonable commercial practices common in the industry
to protect its proprietary and confidential information, including requiring its employees, consultants and agents to be bound in writing by obligations of confidentiality and non-disclosure, and requiring its employees, consultants and agents to
assign to it any and all inventions and discoveries discovered by such employees, consultants and/or agents made within the scope of, and during their employment, and only disclosing proprietary and confidential information to Third Parties pursuant
to written confidentiality and non-disclosure agreements. 
 10.2 Genentech Representations. Genentech hereby represents and warrants
the following to ACI: 

  
  

			
	Research Collaboration and License Agreement Tau	  	30

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 10.2.1 Genentech has the full right, power and authority, and have obtained all approvals,
permits or consents necessary, to enter into this Agreement and to perform all of its obligations hereunder. 
 10.2.2 Genentech has not,
prior to the Effective Date, entered into and shall not, following the Effective Date, enter into any agreement that conflicts in any way with this Agreement or Genentech’s obligations hereunder. 

10.2.3 Genentech follows reasonable commercial practices common in the industry to protect its proprietary and confidential information,
including requiring its employees, consultants and agents to be bound in writing by obligations of confidentiality and non-disclosure, and requiring its employees, consultants and agents to assign to it any and all inventions and discoveries
discovered by such employees, consultants and/or agents made within the scope of, and during their employment, and only disclosing proprietary and confidential information to Third Parties pursuant to written confidentiality and non-disclosure
agreements. 
 10.3 DISCLAIMER. THE WARRANTIES SET FORTH IN SECTIONS 10.1 AND 10.2 ARE IN LIEU OF ALL OTHER WARRANTIES,
EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, VALIDITY, NON-INFRINGEMENT AND ALL SUCH OTHER WARRANTIES ARE HEREBY EXPRESSLY DISCLAIMED. 

ARTICLE 11: INDEMNIFICATION 

11.1 Indemnification by ACI. ACI shall defend, indemnify and hold harmless Genentech, its Affiliates and Genentech Licensees and their
respective officers, directors, employees and agents from and against any and all Third Party liabilities, claims, suits, and expenses, including reasonable attorneys’ fees (collectively, “Losses”), to the extent arising out of
or attributable to (i) the inaccuracy or breach of any representation or warranty made by ACI under this Agreement, or (ii) the negligence or willful misconduct of ACI, its Affiliates or ACI Licensees, or their respective officers,
directors or employees. 
 11.2 Indemnification by Genentech. Genentech shall defend, indemnify and hold harmless ACI, its Affiliates
and their respective officers, directors, employees and agents from and against any and all Losses, to the extent arising out of or attributable to (i) the inaccuracy or breach of any representation or warranty made by Genentech under this
Agreement, or (ii) the development, marketing, approval, manufacture, packaging, labeling, handling, storage, transportation, use, distribution, promotion, marketing or sale of Licensed Products by Genentech; in each case except to the extent
that such Losses are subject to indemnification pursuant to Section 11.1. 
 11.3 Procedure. The indemnities set forth in
this Article 11 are subject to the condition that the Party seeking the indemnity shall forthwith notify the indemnifying Party on being notified or otherwise made aware of a liability, claim, suit, action or expense and that the indemnifying
Party defend and control any proceedings with the other Party being permitted to participate at its own expense (unless there shall be a conflict of interest which would prevent representation by joint counsel, in which event the indemnifying Party
shall pay for the other Party’s counsel); provided, that, the indemnifying Party may not settle the liability, claim, suit, action or expense, or otherwise consent to any judgment, without the written consent of the other Party (such consent
not to be unreasonably withheld). 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	31

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 11.4 Insurance. 

11.4.1 Coverage. Each Party shall maintain, at its own cost, the insurance coverages set forth in this Section 11.4;
provided, however, Genentech has the right, in its sole discretion, to self-insure in part or in whole for any such coverage. 
 11.4.2
ACI. ACI shall have and maintain such type and amounts of Third Party Liability, Commercial General Liability (including contractual liability) and Products Liability insurance as is both (i) required under the laws of Switzerland and
(ii) otherwise normal and customary in the biotechnology industry generally for parties similarly situated. 
 11.4.3 Genentech.
Genentech shall maintain on an ongoing basis coverage for Products Liability and Completed Operations including coverage for Clinical Trials, in the minimum amount of [*****] per occurrence, combined single limit for bodily injury and property
damage liability. 
 11.4.4 Additional Requirements. Except to the extent that Genentech self-insures as authorized under
Section 11.4.1, the following provisions apply: 
 (a) All insurance coverages shall be primary insurance with respect to each
Party’s own participation under this Agreement, and shall be maintained with an insurance company or companies having an A.M. Best’s rating (or its equivalent) of A-XII or better. 

(b) Such Party shall maintain the insurance coverage for at least [*****] years following such Party’s completing the performance of its
obligations under this Agreement. 
 (c) Upon request by the other Party, each Party shall provide to the other Party its respective
certificates of insurance evidencing the insurance coverages set forth in Section 11.4.1. Each Party shall provide to the other Party at least [*****] days prior written notice of any cancellation, nonrenewal or material change in any of
the insurance coverages. Each Party shall, upon receipt of written request from the other Party, provide renewal certificates to the other Party for as long as such Party is required to maintain insurance coverages hereunder. 

11.5 LIMITATION ON DAMAGES. NOTWITHSTANDING ANYTHING CONTAINED IN THIS AGREEMENT TO THE CONTRARY, IN NO EVENT SHALL EITHER PARTY BE
LIABLE TO THE OTHER HEREUNDER FOR ANY SPECIAL, CONSEQUENTIAL OR INCIDENTAL DAMAGES (INCLUDING LOSS OF PROFITS) WHETHER BASED UPON BREACH OF WARRANTY, BREACH OF CONTRACT, NEGLIGENCE, STRICT TORT OR ANY OTHER LEGAL THEORY. THE FOREGOING LIMITATIONS
WILL NOT APPLY TO AN AWARD OF ENHANCED DAMAGES AVAILABLE UNDER THE PATENT LAWS FOR WILLFUL PATENT INFRINGEMENT AND WILL NOT LIMIT EITHER PARTY’S LIABILITY TO THE OTHER PARTY UNDER ARTICLES 11 (INDEMNIFICATION) AND 12 (CONFIDENTIALITY) OF THIS
AGREEMENT. 
 ARTICLE 12: CONFIDENTIALITY 

12.1 Confidential Information. During the Term of this Agreement and for [*****] years thereafter without regard to the means of
termination: (i) ACI shall not use, for any purpose other than the purpose of this Agreement, or reveal or disclose to any Third Party Genentech Confidential Information or Program Confidential Information; and (ii) Genentech shall not
use, for any purpose other than the purpose of this Agreement, or reveal or disclose to any Third Party ACI Confidential Information or 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	32

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 Program Confidential Information. The Parties shall take reasonable measures to assure that no unauthorized
use or disclosure is made by others to whom access to such information is granted. 
 12.2 Exceptions. Notwithstanding the foregoing,
a Party may use and disclose Confidential Information (including any Genentech Confidential Information, ACI Confidential Information or Program Confidential Information) as follows: 

 

	 	(a)	if required by applicable law, rule, regulation, government requirement and/or court order; provided, that, the disclosing Party promptly notifies the other Party of its notice of any such requirement and provides the
other Party a reasonable opportunity to seek a protective order or other appropriate remedy and/or to waive compliance with the provisions of this Agreement; 

  

	 	(b)	to the extent such use and disclosure occurs in the filing or publication of any patent application or patent on inventions; 

  

	 	(c)	as necessary or desirable for securing any regulatory approvals, including pricing approvals, for any Licensed Products; provided, that, the disclosing Party shall take all reasonable steps to limit disclosure of the
Confidential Information outside such regulatory agency and to otherwise maintain the confidentiality of the Confidential Information; 

  

	 	(d)	to take any lawful action that it deems necessary to protect its interest under, or to enforce compliance with the terms and conditions of, this Agreement; and 

 

	 	(e)	to the extent necessary, to its Affiliates, directors, officers, employees, consultants, Genentech Licensees or ACI Licensees (as applicable), vendors and clinicians under written agreements of confidentiality at least
as restrictive as those set forth in this Agreement, who have a need to know such information in connection with such Party performing its obligations or exercising its rights under this Agreement. 

12.3 Certain Obligations. During the term of this Agreement and for a period of [*****] years thereafter and subject to the exceptions
set forth in Section 12.2, Genentech, with respect to ACI Confidential Information, and ACI, with respect to Genentech Confidential Information and Program Confidential Information, agree: 

 

	 	(a)	to use such Confidential Information only for the purposes contemplated under this Agreement, 

  

	 	(b)	to treat such Confidential Information as it would its own proprietary information which in no event shall be less than a reasonable standard of care, 

 

	 	(c)	to take reasonable precautions to prevent the disclosure of such Confidential Information to a Third Party without written consent of the other Party, and 

 

	 	(d)	to only disclose such Confidential Information to those employees, agents and Third Party contractors who have a need to know such Confidential Information for the purposes set forth herein and who are subject to
obligations of confidentiality no less restrictive than those set forth herein. 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	33

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 12.4 Disclosures and Public Announcements. Neither Party shall issue any press release
or other publicity materials, or make any public presentation with respect to the existence of, or any of the terms or conditions of, this Agreement or the programs or efforts being conducted by the other Party hereunder, in each case without the
prior written consent of the other Party. This restriction shall not apply to: 
  

	 	(a)	disclosures to a Party’s attorneys, advisors or investors on a need to know basis under circumstances that reasonably ensure the confidentiality thereof, and 

 

	 	(b)	any future disclosures required by law or regulation, including as may be required in connection with any filings made with, or by the disclosure policies of a major stock exchange; provided that the disclosing Party
(i) use all reasonable efforts to inform the other Party prior to making any such disclosures and cooperate with the other Party in seeking a protective order or other appropriate remedy (including redaction) and (ii) whenever possible,
request confidential treatment of such information. 

 12.5 Scientific Publications. 

12.5.1 If ACI, including its employees, agents, collaborators or consultants, wishes to make a scientific or technical publication,
presentation and/or other related oral disclosure related to ACI IP Rights and Program IP Rights, ACI shall deliver to Genentech a copy of the proposed written publication or an outline of the proposed presentation or oral disclosure at least
[*****] days prior to submission for publication, presentation and/or other oral disclosure. Genentech may then (a) request (within [******] days of the delivery of the publication or outline) modifications to the publication or outline for
patent reasons or business reasons, and ACI shall make such modifications, (b) delete (within [*****] days of the delivery of the publication or outline) any trade secrets or Confidential Information of Genentech included in that publication or
outline, and/or (c) request (within [*****] days of the delivery of the publication or outline) a reasonable delay of no more than [*****] days from the date such delay is requested by Genentech in publication, presentation and/or other oral
disclosure to protect know-how and patentable subject matter. In the event that the ACI does not receive any response from Genentech with respect to the ACI’s proposed written publication or outline of the proposed presentation or oral
disclosure within [*****] days of the delivery of the publication or outline, subject to the terms of this Agreement, ACI shall be free to publish, present or otherwise orally disclose the information contained in such publication or outline. 

12.5.2 If Genentech, including its employees, agents or consultants, wishes to make a scientific or technical publication, presentation and/or
other related oral disclosure related to ACI IP Rights, Genentech shall deliver to ACI a copy of the proposed written publication or an outline of the proposed presentation or oral disclosure at least [*****] days prior to submission for
publication, presentation and/or other oral disclosure. ACI may then (a) request (within [*****] days of the delivery of the publication or outline) modifications to the publication or outline for patent reasons, and Genentech shall make such
modifications, (b) delete (within [*****] days of the delivery of the publication or outline) any trade secrets or Confidential Information of ACI included in that publication or outline, and/or (c) request (within [*****] days of the
delivery of the publication or outline) a reasonable delay of no more than [*****] days from the date such delay is requested by ACI in publication, presentation and/or other oral disclosure to protect know-how and patentable subject matter. In the
event that Genentech does not receive any response from ACI with respect to Genentech’s proposed written publication or outline of the proposed presentation or oral disclosure within [*****] days of the delivery of the publication or outline,
subject to the terms of this Agreement, Genentech shall be free to publish, present or otherwise orally disclose the information contained in such publication or 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	34

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 
outline. 
 12.6 Termination Event. Upon termination, but not expiration, of
this Agreement and upon the request of the disclosing Party, the receiving Party shall promptly return to the disclosing Party or destroy all copies of Confidential Information received from such Party, and shall return or destroy, and document the
destruction of, all summaries, abstracts, extracts, or other documents which contain any Confidential Information of the other Party in any form, except that each Party shall be permitted to retain a copy (or copies, as necessary) of such
Confidential Information (a) for archival purposes, (b) as required by any law or regulation, (c) in the case of ACI, for purposes of exploiting its rights in any Product Reversion Package provided by Genentech pursuant to
Section 9.3.1 or (d) in the case of Genentech, for purposes of exploiting its surviving rights pursuant to Section 9.3.2. 

ARTICLE 13: ARBITRATION 

13.1 Disputes. This Agreement is made on the basis of mutual confidence, and it is understood that the differences, if any, during the
life of this Agreement should freely be discussed between the two Parties. The Parties shall initially attempt in good faith to resolve any significant controversy, claim, or dispute arising out of or relating to this Agreement, or its
interpretation, performance, nonperformance or any breach of any respective obligations hereunder (hereinafter collectively referred to as a “Dispute”) through negotiations between senior executives of ACI and Genentech (or their
respective designee). If the Dispute is not resolved within [*****] days (or such other period of time mutually agreed upon by the Parties) of commencing such face-to-face negotiations, or if the Party against which a claim has been asserted refuses
to attend such negotiations or does not otherwise participate in such negotiations within [*****] days (or such other period of time mutually agreed upon by the Parties) from the date of notice of a Dispute, either Party may, by written notice to
the other, invoke the provisions of Section 13.2. 
 13.2 Arbitration. Subject to Sections 13.1 and 13.3, the
Parties agree to resolve any Dispute exclusively through binding arbitration conducted under the auspices of the International Chamber of Commerce (the “ICC”) pursuant to the Rules of Arbitration of the International Chamber of
Commerce then in effect (the “ICC Rules”). The arbitration shall be conducted in the English language before [*****] arbitrators appointed in accordance with the ICC Rules; provided that at least one such arbitrator shall have had,
by the time of the actual arbitration, at least [*****] years of experience as an attorney and experience in the pharmaceuticals industry so as to better understand the legal, business and scientific issues addressed in the arbitration. Unless
otherwise mutually agreed by the Parties, any arbitration hereunder it shall be brought at the location of the Party which first received the notice required under Section 13.1. Unless agreed otherwise by the Parties, the Parties shall
have [*****] days from the appointment of the last to be appointed of the [*****] arbitrators to present and/or submit their positions to the arbitrators, and the Parties shall have a hearing before the arbitrators within [*****] Business Days of
such submission. The arbitrators shall hear evidence by each Party and resolve each of the issues identified by the Parties. The arbitrators shall be instructed and required to render a written, binding,
non-appealable resolution and award on each issue which clearly states the basis upon which such resolution and award is made. The written resolution and award shall be delivered to the Parties as
expeditiously as possible, but in no event more than [*****] days after conclusion of the hearing, unless otherwise agreed to by the Parties. The Parties shall use all reasonable efforts to keep arbitration costs to a minimum. Each Party must bear
its own attorneys’ fees and associated costs and expenses, as well as an equal share of the fees and costs incurred by ICC and the arbitrators. The Parties shall use all reasonable efforts to make witnesses available for the proceedings. 

13.3 Subject Matter Exclusions. Notwithstanding the foregoing, the provisions of Sections 13.1 and 13.2 shall not apply to any
Dispute relating to: [*****] 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	35

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 [*****]. Notwithstanding anything to the contrary in the foregoing provision of this
Section 13.3, any Dispute relating to Genentech and/or its Affiliate(s)’s assertion of non-infringement of or by any of its activities with respect to ACI IP Rights, including without limitation any assertion by Genentech or its
Affiliates that the making, using, selling, offering for sale and importation of any Tau-Active Antibody(ies) and/or Licensed Product(s) do not infringe ACI IP Rights (“Patent Infringement
Dispute”) shall be subject to the provisions of Sections 13.1 and 13.2, provided that at least [*****] of the [*****] arbitrators provided in Section 13.2 shall have had, by the time of the actual arbitration, at least
[*****] years of experience as a practicing patent attorney registered to practice before the United States Patent and Trademark Office so as to better understand the patent-related issues addressed in the Patent Infringement Dispute. 

13.4 Equitable Relief. Nothing in this Agreement shall be deemed as preventing the Parties from seeking injunctive relief (or other
provisional remedy) from any court having jurisdiction over the Parties and the subject matter of the dispute as necessary to protect either Party’s interests. 

ARTICLE 14: MISCELLANEOUS 

14.1 Assignment and Delegation. Neither this Agreement nor any right or obligation hereunder shall be assignable in whole or in part,
whether by operation of law, or otherwise by ACI without the prior written consent of Genentech. Notwithstanding the foregoing, ACI may assign or transfer its rights and obligations under this Agreement to a Person that succeeds to all or
substantially all of ACI’s business or assets related to this Agreement whether by sale, merger, operation of law or otherwise. If during the term of the Research Program, ACI makes a permitted assignment to a successor in accordance with the
foregoing sentence, Genentech may terminate the Research Program upon notice without terminating this Agreement. This Agreement shall be binding upon and inure to the benefit of and be enforceable by the Parties hereto and their respective
successors and permitted assignees. Any transfer or assignment of this Agreement in violation of this Section 14.1 shall be null and void. 

14.2 Relationship of GNE and Roche. GNE and Roche are jointly referred to in this Agreement as Genentech. Except where either GNE or
Roche are expressly referred to herein, (a) each of GNE and Roche shall be entitled to exercise any rights or perform any obligation attributed in this Agreement to Genentech, and each of GNE and Roche shall be jointly liable for any obligation
attributed in this Agreement to Genentech. Any communication or act by GNE shall be deemed to have been consented by Roche and any act or communication by Roche shall be deemed to have consented by GNE. Except where either GNE or Roche are expressly
referred to herein, ACI shall be entitled to meet its obligation to Genentech by delivering a notice or perform its obligations to either GNE or Roche. 

14.3 Change of Control. No later than [*****] days following the public announcement of a proposed Change of Control event, ACI shall
provide Genentech with written notice of any such Change of Control. Within [*****] days of receipt of such written notice, Genentech shall have the right to terminate this Agreement in accordance with Section 9.3.2. For the purposes of
this Section 14.3, “Change in Control” of ACI means that during the Term of this Agreement (i) ACI shall have become an Affiliate of a Person that is a Competitor; and/or (ii) any sale, lease, exchange or other
transfer (in one transaction or a series of related transactions) of all or substantially all of the assets of ACI shall have occurred to a Competitor; and/or (iii) the stockholders of ACI shall have approved of a plan or proposal for the
liquidation or dissolution of the company; and/or (iv) any Competitor (whether individually or as part of a group) shall have become the owner, directly or indirectly, beneficially or of record, of shares representing more than [*****] of the
aggregate ordinary voting power represented by the issued and outstanding voting stock of ACI. For the purposes of this Section 14.3, “Competitor” means any Person that conducts any research and/or development,
activities, or that manufactures, promotes, 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	36

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 markets, distributes and/or sells any products for [*****], in the biotechnology or pharmaceutical industry.

 14.4 Entire Agreement. This Agreement contains the entire agreement between the Parties relating to the subject matter hereof, and
all prior understandings, representations and warranties between the Parties are superseded by this Agreement, including the Confidential Disclosure Agreement between the Parties dated March 18, 2010, as amended. 

14.5 Amendments. Changes and additional provisions to this Agreement shall be binding on the Parties only if mutually agreed upon, laid
down in writing and signed effectively by the Parties. 
 14.6 Applicable Law. This Agreement shall be construed and interpreted in
accordance with the laws of New York and all rights and remedies shall be governed by such laws without regard to principles of conflicts of law. 

14.7 Force Majeure. If the performance of this Agreement or any obligations hereunder is prevented, restricted or interfered with by
reason of earthquake, fire, flood or other casualty or due to strikes, riot, storms, explosions, acts of God, war, or a similar occurrence or condition beyond the reasonable control of the Parties, the Party so affected shall, upon giving prompt
notice to the other Parties, be excused from such performance during such prevention, restriction or interference, and any failure or delay resulting therefrom shall not be considered a breach of this Agreement. 

14.8 Severability. The Parties do not intend to violate any public policy or statutory common law. However, if any sentence, paragraph,
clause or combination of this Agreement is in violation of any law or is found to be otherwise unenforceable, such sentence, paragraph, clause or combination of the same shall be deleted and the remainder of this Agreement shall remain binding;
provided that such deletion does not alter the basic purpose and structure of this Agreement. 
 14.9 Notices. All notices, requests,
demands, and other communications relating to this Agreement shall be in writing in the English language and shall be delivered in person or by registered mail, international courier or facsimile transmission (with a confirmation copy forwarded by
courier or registered mail). Notices sent by mail shall be sent by first class mail or the equivalent, registered or certified, postage prepaid, and shall be deemed to have been given on the date actually received. Notices sent by international
courier shall be sent using a service which provides traceability of packages. Notices shall be sent as follows: 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	37

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

			
	Notices to Genentech:	  	with a required copy to:
		
	 Genentech Inc.
 1 DNA Way

South San Francisco, CA 94080, USA
 Attention: Corporate
Secretary
 Telephone: [*****]
 Facsimile: [*****]
	  	 Genentech Inc.
 1 DNA Way

South San Francisco, CA 94080, USA
 Attention: Vice President,
Genentech Partnering
 Telephone: [*****]
 Facsimile:
[*****]

		
		  	and
		
		  	 F. Hoffmann-La Roche Ltd
 Grenzacherstrasse
124
 4070 Basel
 Switzerland

Attn: Corporate Legal Department
 Telephone: [*****]

Facsimile: [*****]

		
	Notices to ACI:	  	with a required copy to:
		
	 AC Immune
 Pare scientifique EPFL, PSE-B,

CH-1015 Lausanne, Switzerland
 Attention: CEO

Telephone: [*****]
 Facsimile: [*****]
	  	 VISCHER Ltd. Attorneys at law

Aeschenvorstadt 4
 CH-4051 Basel, Switzerland

Attention: Dr. Matthias Staehelin
 Telephone: [*****]

Facsimile: [*****]

 Either Party may change its address for notices or facsimile number at any time by sending written notice by
courier or registered mail to the other Party. 
 14.10 Independent Contractor. Nothing herein shall create any association,
partnership, joint venture, fiduciary duty or the relation of principal and agent between the Parties hereto, it being understood that each Party is acting as an independent contractor, and neither Party shall have the authority to bind the other or
the other’s representatives in any way. 
 14.11 Waiver. No delay on the part of either Party hereto in exercising any power or
right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any power or right hereunder preclude other or further exercise thereof or the exercise of any other power or right. No waiver of this Agreement or any
provision hereof shall be enforceable against any Party hereto unless in writing, signed by the Party against whom such waiver is claimed, and shall be limited solely to the one event. 

14.12 Interpretation. This Agreement has been prepared jointly and no rule of strict construction shall be applied against either
Party. In this Agreement, the singular shall include the plural and vice versa and the word “including” shall be deemed to be followed by the phrase “without limitation.” The section headings contained in this Agreement are
inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement. 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	38

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

			
	 CONFIDENTIAL
	  	   FINAL EXECUTION VERSION

  

 14.13 Counterparts. This Agreement may be executed in counterparts, each of which
together shall constitute one and the same Agreement. For purposes of executing this agreement, a facsimile copy of this Agreement, including the signature pages, will be deemed an original. 

14.14 License Survival During Bankruptcy. All rights and licenses granted under or pursuant to this Agreement are, and shall otherwise
be deemed to be, for purposes of Paragraph 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Paragraph 101(35A) of the U.S. Bankruptcy Code. The Parties agree that Genentech, as a licensee
of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against ACI,
including under the U.S. Bankruptcy Code, Genentech shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and the same, if not already
in Genentech’s possession, shall be promptly delivered to Genentech upon any such commencement of a bankruptcy proceeding upon written request therefor by Genentech. 

*        *        *       
 *        * 

  
  

			
	Research Collaboration and License Agreement (Tau)	  	39

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 IN WITNESS WHEREOF, the Parties have executed this Agreement by their duly authorized
representative. 
  

									
	AC Immune SA	 		 	Genentech, Inc.
					
	By:	 	 /s/ Andrea Pfeifer
	 		 	By:	 	 /s/ Steve Krognes

	Name:	 	Andrea Pfeifer	 		 	Name:	 	Steve Krognes
	Title:	 	CEO	 		 	Title:	 	CFO
				
		 		 		 	F. Hoffmann-La Roche Ltd
					
		 	 /s/ A. Muhs
	 		 	By:	 	 /s/ Sophie Kornowski-Bonne

		 	A. Muhs	 		 	Name:	 	Sophie Kornowski-Bonne
		 	CSO	 		 	Title:	 	Global Head Roche Partnering
					
		 		 		 	By:	 	 /s/ Stefan Arnold

		 		 		 	Name:	 	Stefan Arnold
		 		 		 	Title:	 	Head Legal Pharma

  
  

			
	Research Collaboration and License Agreement (Tau)	  	

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 Exhibit A 

ACI Patents 
  

											
	 Applicant
	 	 Application No
	 	 Patent
	 	 Application date
	 	 lapsed
	 	 Title

	 [*****]
	 	[*****]	 		 	[*****]	 		 	[*****]
	 [*****]
	 	[*****]	 	[*****]	 	[*****]	 	[*****]	 	[*****]
	 [*****]
	 	[*****]	 	[*****]	 	[*****]	 	[*****]	 	[*****]
	 [*****]
	 	[*****]	 	[*****]	 	[*****]	 	[*****]	 	[*****]
	 [*****]
	 	[*****]	 	[*****]	 	[*****]	 	[*****]	 	 [*****]

Tau [*****]

  
  

			
	Research Collaboration and License Agreement (Tau)	  	

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 Exhibit B 

Research Plan 
 [*****]

 AC Immune Activities 
 [*****] Tau 

[*****] pTau [*****] 
 [*****] 

[*****] Tau [*****] Tau [*****] 
  

  
  

			
	Research Collaboration and License Agreement (Tau)	  	

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 [*****] pTau [*****] 

[*****] 
 [*****] ptau [*****]

 [*****] tau [*****] 
 [*****]
tau [*****] 
 [*****] pTau) 
  

  
  

			
	Research Collaboration and License Agreement (Tau)	  	

 CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 

UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT 

REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL 

HAS BEEN FILED SEPARATELY WITH THE COMMISSION. 
  

 Exhibit C 

Antigens for Discovery Antibodies 
  

					
	 Description
	  	 Vaccine
	 	
Antigens*: Sequence*’*, length (n), sequence ID number

	[*****] Tau	  	[*****]	 	[*****]

	 [*****] Tau
 [*****] Tau
	  	[*****]	 	[*****]

	[*****] Tau	  	[*****]
	 	[*****]

	[*****] Tau	  	[*****]	 	[*****]

  

	
	 [*****] Tau (Tau441). [*****]

  
  

			
	Research Collaboration and License Agreement (Tau)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}]]